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PART I 

CHAPTER I 
INTRODUCTION 
Since the development of transplantation of tissues, much effort has been 
directed towards the acceptance of transplanted grafts. Many methods have 
been developed to prevent or delay the rejection reaction. Some of them are 
used in clinical transplantation, involving immunosuppression of the host by 
certain drugs, hormones and by anti lymphocyte serum, which contains anti-
bodies directed against the lymphocytes of the host. These methods, if care-
fully applied, may indeed prevent rejection of the grafts in a proportion of 
the patients. However, treatment with these drugs can be deleterious for the 
host, for suppression of the immune response increases the susceptibility for 
infection and probably also for tumors [lOb]. In fact, many recipients of organ 
transplants still die from sepsis [261]. 
Thus, any type of immunosuppression is still associated with a noxious effect 
on the host. A solution for these transplantation problems might be provided 
by the oldest principle in the achievement of graft acceptance, namely enhance-
ment. Recently Snell [257] defined enhancement as: the enhanced or prolonged 
growths of allografts, due to the presence in the graft recipient of allo-antibody 
directed against the allo-antigens of the donor [257]. In other words, a graft is 
protected by enhancing antibodies, that are not directed against the recipient 
as is the case for A.L.S., but against the donor antigens. 
Evidence has been accumulated for a more biological function of immuno-
logical enhancement. For example, enhancement might be responsible for the 
occurrence of tumors in man [112], the favourable results in human kidney 
transplantation and for the acceptance of the foetus during pregnancy [ 114] 
as suggested by the findings in this thesis (chapter VIa). Even tolerance might 
in fact be mediated by enhancing antibodies [113]. 
Enhancing antibodies are, in contrast to the present immunosuppressive 
treatment, probably not harmful for the recipient, and thus might constitute 
a better solution for the problems in clinical transplantation. Enhanced tumor 
growth has always been the most reproducible example of the phenomenon. 
The efforts to induce immunological enhancement of grafts of normal tissue 
were until recently largely unsuccessful. In order to increase the possibilities 
of eventual clinical application of immunological enhancement, more infor-
mation on the exact requirements to induce enhancement of a normal tissue 
graft is clearly needed. This is the very purpose of the experiments described 
in this thesis. 
Skin was chosen as graft model, because skin grafting is simple to complete 
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and the outcome of enhancement of skin grafts seems a better indicator for the 
clinical situation than that oftumor grafts. In the first 4 experiments enhance-
ment was studied with skin allografts, i.e. skin grafts exchanged between mem-
bers of one species. Special mouse strains have been used in these four experi-
ments in such a combination, that donor and recipient only differed at one 
single histocompatibility locus. Such a monospecific disparity was chosen on 
purpose, for enhancement might then be obtained more easily. Immunological 
enhancement of skin heterografts was tested in the rat species. 
The reason that most of our experiments were done with mice as the labora-
tory animal of choice, is, that in this species the genetics of tissue transplan-
tation have been studied most extensively. In addition, the largest number of 
inbred strains is available within this species, which enables extensive studies 
of transplantation immunology. 
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CHAPTER II 
THE REJECTION REACTION 
Immunological enhancement is supposed to have a certain effect on the 
immune reaction. Therefore, some aspects of the immune reaction will first 
be described, before discussing the problems around immunological enhance-
ment. 
Immune reactions are elicited by antigens, which are foreign to the host. 
Transplantation of normal or neoplastic tissue confront the genetically different 
recipient with foreign antigens and the ensuing immune response results in 
rejection of the transplanted tissue. These antigens, which are mainly located 
on the cell surface, are the so-called transplantation antigens. The severity 
of the rejection reaction depends upon the degree of histo-incompatibility, i.e. 
the disparity between donor and recipient, which is determined by multiple 
genes, the histocompatibility genes or H-genes. It has been shown for several 
species that the most important histocompatibility antigens are governed by 
genes of two closely linked loci. A graft will be permanently accepted when all 
histocompatibility antigens of donor and host are identical as is the case for 
identical twins and animals of inbred strains. The structure of the trans-
plantation antigens is not yet completely understood. Its immunological 
specificity is under the control of genes at many loci, which are most extensively 
studied in mice. At least 15 H-loci are present in this species, of which one 
chromosomal region, the H2-locus is the strongest locus, as evidenced by the rate 
of rejection of skin grafts [258, 256] (table 1). Over 30 specificities have already 
been identified in this locus. The H2-antigens are present on virtually all cells, 
but especially concentrated on the lymphoid cells. Comparable loci in man, 
rats, Rhesus monkeys and dogs are respectively the HL-A, Ag-B, RhL [1 Ob J and 
DL-A locus [286, 288b]. HL-A antigens however are not detectable on erythro-
cytes, while the erythrocytes of rodents do contain tissue antigens in sufficient 
quantity to make them demonstrable with special serological techniques. 
The rejection of a graft involves a complex combination of humoral and 
cellular response [230, 231]. The cellular response seems to constitute the most 
important part of the acute rejection [233]. In 1944, Medawar described an 
infiltration of predominantly mononuclear cells during skin graft rejection 
[180]. Attempts to transfer immunity to skin grafts with serum failed con-
sistently, whereas adoptive transfer of immunity appeared to be possible with 
sensitized lymphoid cells [27, 184, 185, 200]. Earlier, it was shown that the 
delayed hypersensitivity reaction, which is similarly caused by a cellular 
reaction [18, 236, 277a], can be adoptively transferred by mononuclear cells 
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-en Table 1. The H2~locus ** 
HZ Specificities (old symbols at top) 
alleles A Db C D E F G H I J K .M N P Q S V Y A' B' C' D' Ed Dk K b inbred strains 
H2" 
H2b 
H2C 
H211 
H28 
H2f 
H2g 
H2h 
H2' 
H21 
H2k 
- 3 4 5 6 - 8 - 10 11 13 14 -
- 2 - - 5 6 - - - 14 -
*-345* 8 - * 13 * 
3 4 - 6 - 8 - lO - 13 14 -
3 
+- -
5 6 
7 8 9 * 
13 * * 
* 
- 2 - - - 6 * ? * * 14 * 
2 3 - 5 6 * 8 * * 11 - ? * 
* - 3 4 5 6 * * * * 13 * * 
---- 6?-* --* 
- 3 - 5 8 11 - -
* 
25 27 28 29 -
22 - 27 28 29 -
* * 27 38 29 - * * 
27 28 29 - 31 -
* 25 27 28 29 30 * * 
* 
27 - * * 
22 * * * * * 31 
* * * * * 
22 * * * * * 
22 ? ? * * * * * 
25 - 32 
A AKR.K 
33 Cb?BL/10 C57BL/6 C57L STA 129 
C3H.S\V CC 57BR CC 57\V D 1.LP 
* D 1.C 
DBA/2 BALB/c C,BLJKs B,..D, 
ST.T6 WH YBLJRr YBRJWi 
* STOL, 
* A.CA B10 Jvi 
H2G 
H2H 
33 H21 
* JK/St 
AKR C,H CBA CH, C,BRjcd 
C., D,.ST MA lv!AJMY CE RF 
STB 101 C,BR/a 
H21 
H2m 
H2n 
H2P 
H2q 
H2' 
H2' 
6 ? * lO * 22 - ? ? * * * * * 1/St N/St (?) 
* - 3 - 5 - - 8 - * 11 13 * - - * 
1 - - - 5 6 * 8 * 10 - 14 * 
* - 3 - 5 6 - - - * * 16 * 
3 - 5 6 - - - - 11 13 - - 17 -
* - 3 - 5 - - 8 * 11 * * 
* 3 - 5 6 7 - - * - - * - 19 * 
* untested 
** from "Biology of the Laboratory !\•louse" [256] 
* 27 28 29 30 * 
* ? ? * * * 
* - * 
* 27 28 29 30 * 
25 - * 
28 
* * 
* * 
* * 
* * 
* * 
AKR.~vi 
FjSt 
P C,H.NB BDP(?) 
DBAJ, B,..Y(?) CjSt BUB 
RIIIJWy LP.RIII(?) 
A.SW SJL 
[59, 158]. However, there is also evidence for rejection by antibodies only, as 
will be discussed later in this chapter. 
In view of the purpose of this work, namely the investigation of the immuno 
inhibiting effect of enhancement, it seems useful to divide the immune reaction 
into three different components. Thus it will be possible to speculate where in 
the immune reaction the enhancing antibodies exert their inhibiting effect 
(fig. 1). 
rejection reaction 
1-= ~ ~ -00 
-00 
- .. 
- .. 
- .. 
- .. 
:··-:-- .. 
• 1-- •• 
' ' : ,-- .. 
!.._.!_ •• 
graft immune 
apparatus 
~ =graft 
0 = rejected graft 
0 0 = immune apparatus 
e e = stimulated immune apparatus 
Fig. l. Simplified scheme of rejection reaction 
l. Afferent component: the transport of antigenic information to the immuno-
competent cells. 
2. Central component: the processing of the antigens and the activation of 
the lymphoid tissue. 
3. Efferent component: the appearance of humoral and cellular factors in the 
circulation and their subsequent activities which lead to graft rejection. 
1. Afferent component 
It is not known how exactly the antigenic information reaches the immuno-
competent cells. These cells may either move to the antigens or the antigens 
may be transported as free molecules or bound to recipient cells. Some evidence 
exists that the antigens are transported via the lymphatic drainage to the 
regionallymphe nodes. Recently Barker and Billingham provided more argu-
ments in favor of this concept by showing that skin flaps, devoid of lymphe 
drainage, will not sensitize the host [11, 12]. 
Many investigators attribute the conveyance of antigens to the macro-
phages, that also seem to play a role in retaining certain antigens for longer 
periods of time [233]. Results of some in vitro [226a J and in vivo [82] studies 
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suggest that lymphoid cells need macrophages to elicit an immune response. 
Noltenius e.a. [208] even attribute an antibody producing quality to the macro-
phages. They found antibody producing macrophages with a modified J erne-
plaque technique (see page 63). In addition, an immunosuppressive effect of 
anti-macrophage serum has been demonstrated, but a significant efficacy 
could only be achieved following stimulation with low antigen doses [5, 76]. 
Antigens which stay in the lymphe nodes, remain either extracellular in the 
follicles or intracellular in the medullary macro phages [I J. The persistance of 
antigen is supposed to be required for the complete differentiation of immuno-
competent cells into antibody forming cells [264, 209, 1]. Indeed some authors 
[102, 280] demonstrated that the presence of antigens is prerequisite for the 
continuous synthesis of i9S- and 7S-antibodies. 
2. Central component 
Although it is not yet known in detail how the antigens stimulate those lymph-
oid cells, which will initiate the rejection reaction, much information on this 
subject has been recently accumulated. 
The antigen-sensitive cell. The lymphocytes which respond to antigenic 
stimulation are called the antigen sensitive cells or immuno-competent cells. 
The way they respond is represented in a xyz-scheme [45]. The antigen 
sensitive cell or x-cell becomes by antigenic stimulation a sensitized progenitor 
cell or y-cell. The y-cell is transformed into antibody producing z cells by 
further contact with the antigens [264]. Obviously this scheme does not 
represent more than a very crude representation of the totality of cellular 
changes that arise during antigenic stimulation. Some theories exist about the 
way the x-y-transformation of the antigen sensitive cell occurs. 
Receptor site. It is suggested that the antigen is recognized by a special 
receptor site of the antigen sensitive cell [172, 218, 239, 295]. The structure 
and binding capacity of this receptor site is probably similar to the antibody 
which that cell will finally produce. A controversy exists about the amount of 
receptor sites present on one antigen sensitive cell. Some favor the concept of 
multipotential immunocompetent cells [214], others give credence to the 
existence of specific receptor sites on individual immunocompetent cells [207]. 
McConnell e. a. [214 J specifically differentiated between IgM like receptors and 
IgG like receptors on rosette-forming cells in mice. 
As early as 1935 the lymphocytes were recognized as the source of antibody 
production. The indirect fluorescence technique revealed that plasma cells 
contain antibodies. Some investigators now claim that both lymphocytes as 
well as plasma cells can produce antibodies. Lymphocytes probably transform 
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into plasma cells [104]. Singhal [245] suggested that the immune response is 
initiated in the bone marrow, but completed in lymph nodes and spleens. 
Much of the initial information about the immunocompetent cell came 
from studies of the Graft Versus Host reaction. A Graft Versus Host reaction 
occurs when lymphoid cells are injected into allogeneic or heterogeneic reci~ 
pients which are unable to reject those lymphoid cells. The grafted cells react 
immunologically to their new host. In this way a reversed homograft reaction 
occurs, that is characterized by a "wasting disease". Small lymphocytes were 
shown to convey the Graft Versus Host activity [93, 94, 122]. Hence they are 
thought to represent the immunocompetent cells. 
In fact the small lymphocytes appear to be precursors for the cells that 
regulate antibody production and are also responsible for the so-called cell-
mediated graft destruction (56, I 73]. Gowans [93] isolated small lymphocytes 
from the thoracic duct and demonstrated that these cells continuously recir-
culate between lymphe-channels and the blood stream. This cell population 
has a very extended life span and carries the immunologic memory [92]. 
The stem cells for the immunocompetent cells are situated in the bone mar-
row. Following antigenic stimulation, many small lymphocytes transform into 
large lymphoblasts. The thymus has a regulatory role. Namely the cell-
mediated reaction is, in contrast to the humoral response, predominantly 
thymus dependent, and is depressed by neonatal thymectomy. Thus the cel-
lular response is mediated by Thymus-dependent lymphocytes (T-cells) [198]. 
These T-cells are small lymphocytes that recirculate in the blood stream and 
are concentrated in the paracortical areas of the lymphenodes. Conversely the 
humoral response is bone marrow dependent. The bone marrow dependent 
areas are located in the cortical zone of the lymphenodes, where the B-cells can 
be detected, or plasma cells that are responsible for the humoral response. 
3. Efferent co:m.ponent 
During the efferent phase, the actual rejection takes place by a combination of 
humoral and cellular reactions [186]. It is not yet known how the activated 
small lymphocytes or T-cells kill the cells of the graft [226b, 277a], but one 
assumption is, that these cells secrete noxious factors following contact with 
target cells. Such an intensive cell to cell contact has been reported [197]. 
There is also evidence for interaction between lymphocytes and macrophages 
by which phagocytosis occurs. Sensitized lymphocytes probably produce a 
factor, the Migration Inhibiting Factor (M.LF.), that inhibits the migration 
of macro phages. 
The role of the humoral reaction in the rejection of skin and tumor grafts is 
thought to be of minor importance, but will be more extensively discussed in 
view of the characteristics of enhancing antibodies. Participation of immuno-
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globulins in the rejection reaction has been described. Firstly, neoplastic cells of 
reticular tissue are in vivo as well as in vitro more sensitive to the cytotoxic 
action of antibodies, than other tumor cells. Resistance to humoral antibodies 
seems to be related to the concentration of isoantigen on cell surfaces [187, 
189]. Cells more densely covered by antigenic sites are more vulnerable. 
Secondly, several investigators described a deleterious effect on grafts by 
passive transfer of immunity by antiserum [15, 61, 63, 64, 91, 106, 107, 204, 
263, 265, 266, 267, 284]. Hasek [106] reported the destruction by antiserum 
of a skin graft present on a duck tolerant to the heterologous donor duck. 
Recently, the abolition of tolerance by antiserum was also demonstrated in 
rats [109, 166]. Najarian and Feldmann [204] and Kretschmer and Perez-
Tamayo [156, 157] showed accelerated rejection of skin grafts in mice and 
rats respectively by immune lymphoid cells kept in a diffusion chamber. Yet 
the antibodies alone could never account for the graft rejection observed in 
those experiments, where the recipients still have an intact immune apparatus, 
for then the cellular response may play a major role in rejection. Evidence for 
a synergistic effect of immune lymphoid cells and antibodies has been provided 
by Batchelor [15]. A clear cut effect of serum alone was obtained in the 
rejection of kidney allografts in dogs by Clark e. a. [63]. They transferred the 
kidney, after implantation into specifically sensitized irradiated dogs, back to 
the original donor. Rejection occurred then within two hours. Also in clinical 
transplantation, hyperacute reactions are observed if the recipients possess 
antibodies directed against the donor antigens. 
A dual effect of serum has also been shown [44, 88]. The growth of a mouse 
Ehrlich ascites tumor in guinea pigs was inhibited when incubated with 
specific xenogenic y2-immunoglobulin and enhanced with the F(ab)2-fragment 
of the serum. 
Thus, by the injection of antiserum, either an accelerated rejection or en-
hancing effect can be expected. For clinical transplantation it would be 
of great value to be able to eliminate those factors of the serum that lead to 
rejection. Therefore the enhancing properties of antisera were tested in the 
experiments that are described in this thesis. 
Suppression of the rejection reaction 
Whereas the rejection reaction is still not completely understood, many studies 
have already been undertaken to find methods for the prevention of the 
occurrence of this reaction. Clinical transplantation would indeed not be 
possible without the use of immunosuppressive agents, like corticosteroids, 
Azathiopurine and Actinomycin. In recent years, an effective serum has been 
developed by injecting lymphoid cells of the recipient into allogeneic or 
heterogeneic animals. This anti lymphocyte serum (A.L.S.) is currently being 
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tested in clinical trials. Although these methods are to some extent effective in 
preventing a rejection reaction, one principal drawback of their use is the 
noxious effect on the recipient. 
A safer way to achieve immunological unresponsiveness might proceed from 
two immunological phenomena, which have been known for a long time, 
namely immunological enhancement and tolerance [160, 179, 182]. The 
following definition of tolerance has been given by Medawar: "If an animal is 
exposed to an antigen before it has developed the capacity to react against it, 
the development of that capacity is delayed and, under certain circumstances, 
may be indefinitely postponed." Immunological enhancement, as mentioned 
before, is mediated by specific antibodies directed against the donor antigens. 
Clinical application is not yet feasible, because of the limited knowledge about 
these phenomena, that even might be closely related [113, 163]. In the pre-
sented experiments immunological enhancement of normal tissues was studied. 
The results may lead to a better understanding and, eventually, to clinical 
application of this interesting modification of the immune response. 
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CHAPTER III 
IMMUNOLOGICAL ENHANCEMENT 
1. History 
Enhancement of tumors 
Enhancement has been described by Kaliss [139], one of the early investigators 
of this phenomenon, as "the successful establishment of a tumor homograft and 
its progressive growth (usually to death of the host) as a consequence of the 
tumor's contact with specific antiserum in the host". As with so many new 
discoveries this was detected by chance in the course of investigations into the 
immune therapy of cancer. In the beginning of this century it was already 
known, that after the rejection of a transplantable tumor, immunity had been 
developed against a second inoculation of the same tumor [86, 90]. Attempts to 
produce immunity by injections of non living tumor tissue, succeeded in some 
instances. Frequently however, a paradoxa! effect was noted. The expected 
accelerated rejection of the test graft did not occur after pretreatment with 
either frozen, lyophilized or otherwise killed tumor tissue of the same antigenic 
structure. 
The first to describe this phenomenon were Flexner andJobling in 1907 [86], 
who reported the progressive growth of a rat sarcoma in some rats, which had 
previously rejected a first graft of the same tumor. Later, enhancement was 
studied mostly with transplantable tumors indigenous to inbred strains of mice 
or rats. One of the first systematic investigations with non-inbred animals was 
undertaken by Casey in 1932 [49, 50, 51, 52, 53). Using the transplantable 
Brown-Pearce rabbit epithelioma, he induced its progressive growth in allo-
geneic hosts by previous injections of frozen tumor tissue. This 9z-effect, as 
he called it, was tumor-specific because inoculations of frozen Brown-Pearce 
tumor did not affect the growth of a mouse carcinoma or sarcoma. Surprisingly 
the "enhancing material" was still effective when injected two weeks after the 
tumor inoculation. Rabbits injected 8-10 times with this substance even ex-
hibited enhancement of a subsequent tumorgraft 7 months later! The author 
did not try to exclude tolerance as the cause of his findings, for tolerance was 
not yet known at this time. 
Following Casey's work, which already demonstrated so many characteristics 
of the enhancement phenomenon, numerous investigators have explored this 
field. 
The characteristics of the tumor 
The importance of the characteristics of the tumor grafts was pointed out by 
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Fig. 2. Active enhancement of tumor grafts 
Snell e.a. [252]. Pretreatment with specific lyophilized tumor tissue in mice, 
enhanced the growth of strain A carcinoma in I 00% of the treated animals 
(fig. 2), whereas a leukemia was rejected by the same specific enhancing treat-
ment. A series of injections of lyophilized tissue prior to the isogenic tumor in-
oculation gave various results amongst 9 different tumors, studied in 7 different 
strains of mice [253]. Again growth of the leukemia was inhibited. Later it was 
shown that enhancement ofleukemia did not occur because of the exceptionally 
high sensitivity of cells of lympho-reticular origin to the cytotoxic action of 
antibodies. 
With other tumors enhancement occurred to various degrees, depending On 
host strain and tumor type. The growth of fibrosarcoma L 946 was either in-
hibited or stimulated, depending on the strain of mice in which it was inocu-
lated. Of two strain A tumors, Sarcoma I and the 15091" tumor, a more con-
sistent and significant enhancement was obtained with the Sarcoma I [139]. 
For this reason this Sa I tumor was often used in the classical experiments of 
Kaliss [132, 140]. Inoculation of the Sa I tumor of A mice in C5,BL/Ks mice 
first led to a period of heightened resistance starting on the third day and 
subsiding after 2-3 weeks. Only afterwards enhancement of a second graft was 
observed. 
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According to the theory of Moller [190], the different behaviour of the 
various tumors is determined by the concentration of antigenic receptors on 
the surface of the tumor cells. This hypothesis will be discussed later in more 
detaiL 
The condition of the tumor-cell 
Inoculations of killed tissue as initial immune stimulus more often led to en-
hancement than when a live graft was used. The enhancing substance was 
present in the frozen tumors used in Casey's e.xperiments and in the lyophilized 
tissue of Snell [252, 253, 254] and Kaliss [144]. The enhancing factor could 
not be isolated by differential centrifugation nor by tumor filtration through 
Selas or Berke-field filters [254] or by ultrafiltration of tumor supernatant [135]. 
Theories 
The variety of experimental models and of subsequent results did not lead to a 
better understanding of this phenomenon but instead brought about consider-
able confusion. Casey related the "xyz" -effect to a growth stimulating factor, 
present in tumors. Kaliss [134, 143] thought of "conditioning the host", and 
Billingham, Brent and Medawar [23] of "actively acquired tolerance". 
At this point a phenomenon, probably related to enhancement, namely 
antibody mediated humoral unresponsiveness, should briefly be discussed. This 
phenomenon comprises the suppression of the humoral response towards 
various antigens by antibodies directed against those antigens. Many authors 
have postulated a similarity between this phenomenon and the process of 
immunological enhancement. However, it should be kept in mind that the 
antibody mediated humoral unresponsiveness is essentially concerned with 
humoral immunity, while the rejection of grafts, - in particular those of skin 
and tumor tissue - is primarily effected by a cellular immune response. Sup-
pression of the latter is therefore equally important from the clinical point of 
VIew. 
Yet, the data on antibody mediated humoral unresponsiveness cannot be 
disregarded entirely in the discussion on clinical transplantation because the 
suppression of both the humoral- and the cellular response by antibodies 
could be based on the same principle. Therefore some examples of antibody 
mediated humoral unresponsiveness will be presented throughout this chapter, 
although it is not implied that we are necessarily dealing with an identical 
mechanism. A more detailed discussion will follow at the end of this chapter. 
Specific immunological effect 
It was the merit of Kaliss and co-workers to clarifY to some extent the mystery 
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concerning the phenomenon of enhancement. First, they showed that pre-
treatment with normal homologous tissue could also lead to enhancement of 
subsequently inoculated tumor tissue of the same strain [142]. Furthermore, 
they demonstrated that the effect of the pretreatment was dose-dependent. In 
a certain mouse strain combination, where the graft normally grows in 50o/0 of 
the untreated recipients, "conditioning of the host" could lead to immunity 
when very small doses of antigen were used, while larger doses caused en-
hancement [133, 134]. These observations did not favour the idea of a growth 
stimulating substance being the active principle, but rather suggested a spe-
cific effect of the petreatment on the immune mechanism. Although Casey was 
the originator of the "growth stimulating substance" hypothesis, his own results 
in fact supported tbis latter view, wbich will be discussed below. 
Enhancing antibodies 
Conclusive evidence for the involvement of the immune system was provided 
by Kaliss: Antiserum prepared in Cs,BL/Ks mice by 6 intraperitoneal in-
jections of Sarcoma I tumor enhanced its growth, when injected seven days 
prior to the inoculation of the tumor in an untreated C5,fKs mouse [132] 
(see fig. 3). 
passive enhancement of tumors 
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Fig. 3. Enhancement of tumor grafts by passive transfer of anti-tumor serum 
The passive transfer of enhancement, or passive enhancement is since a crucial test in 
enhancement studies (fig. 3). 
In certain circumstances pretreatment with tumor or normal tissue appa-
rently has such an effect on the immune system, that antibodies are formed 
with enhancing capacities. These antisera specifically prolong the survival 
of those grafts, that are isogenic with the very antigens that elicited the anti-
bodies [136, 137]. The activity of these sera is associated with the y-globulin 
fractions [138, 141, 145]. 
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Still, the questions remained, how these immunoglobulins are produced, how 
they exhibit their protective action and which antibodies or fragments are 
involved. The protection of a graft by antibodies seems to run counter to the 
evidence of their participation in the rejection reaction [15, 63, 107, 204]. 
The occurrence of accelerated rejection of a tumor, injected within the first 
two weeks after the inoculation of a live allogenic tumor graft, plus an in-
creasing number of surviving tumors, when grafting was performed later, 
suggested that enhancing antibodies occur rather late after immunization 
[57, 140]. Enhancement of tumor grafts has even been reported after an inter-
val of 40 weeks after the first inoculation [50]. These findings suggest that more 
than two weeks after tumor inoculation, antibodies with enhancing capacities 
are formed. The production of these enhancing antibodies may be continued 
for 40 weeks. For comparison the peak of hemagglutinin production was found 
to be at about 15 days after the inoculation of the tumor and a titer was present 
for at least 8 months [138]. 
Dosage and antibody titer of serum 
The minimum dosage of antiserum effective in passive enhancement is often 
quite smalL 0.1 fLl of antiserum daily was sufficient in several experiments 
[14, 67, 89, 110, 126]. Some evidence even exists that small amounts of anti-
serum give a better passive enhancement [88]. Kaliss [139] noted a sup-
pression of antiserum in volumes of0.2 ml and an enhancement of growth with 
smaller amounts. Furthermore, Moller [190] reported either an inhibiting or 
enhancing effect by the use of large doses and varying degrees of enhancement 
with small doses. Only one injection of antiserum is often sufficient. It can in 
certain cases successfully be injected as long as 10 days after tumor grafting 
[140]. 
A correlation between the antibody titer against donor cells and the effectiveness 
of antiserum has been observed by some authors. Moore and Pereira [199] 
noted that after active immunization of mice, the occurrence of lower levels 
of antibodies correlated with immunity and higher levels with enhancement. 
Other investigators [14, 57, 155] also described very high antibody levels in 
concurrence with active enhancement in mice. A similar trend has been re-
ported with passive enhancement, namely that hyperimmune sera with high 
haemagglutinating titers were most effective [2, 271]. 
Antibody-structure [168] 
There is still no general agreement about which type of antibody and which 
fragments are responsible for the enhancing phenomenon. 
The antisera are usually obtained from hyperimmunized animals. The 
26 
enhancing quality of antibodies mostly increases with time after immunization 
and with the number of immunizations [67, 71]. In most animal species the 
first antibodies to appear after a primary antigenic stimulus are the 19S-
globulins (lgM), followed by the 7S-immunoglobulins (IgG) [85, 153, 280]. 
Repeated immunizations lead to the formation of IgG [153]. Hence one would 
expect those golbulins to be responsible for enhancement. Indeed the 7S-
immunoglobulins were found to be responsible for the induction of tumor 
enhancement [28, 272, 273, 276] and the inhibition of the immune response of 
antigen stimulated animals [195], whereas the 19S-antibodies were 100-200 X 
less effective [193]. IgG is also more effective in antibody mediated humoral 
unresponsiveness. The 7S-globulins of a homologous hyperimmune antiserum 
to bacteriophage •1xl74 in guinea pigs were much more effective that 19S-
antibodies to prevent antibody formation to X bacteriophage [84]. 
The 7S-immunoglobulins can be separated in a fast and slow portion, re-
spectively the IgG-y1- and IgG-y2-fraction. Tokuda and Me Entee [276] and 
Irvin e.a. [129] more specifically denoted the slow IgG-fraction, the 7Syz-
globulin as the agent responsible for passive enhancement of Sarcoma tumor 
in mice. This was confirmed by Takasugi and Hildemann [272, 273]. In 
their experimental model, which will be further discussed later on, 7S-y2 was 
responsible for enhanced tumor growth in mice. IgG-y1 and IgM were not 
effective in this respect. Haemagglutinating properties were found in IgM and 
IgG-y1 and IgG-y2. Only IgM and IgG-y, had cytotoxic properties. It had 
already been shown by Nussenzweig [210] that IgG-y2 was able to cause 
haemolysis and he concluded that only IgG-y2 can bind complement. In 
contrast to these findings Voisin [284] previously had reported the enhancing 
effect of the fast 7S-y1-fraction of mouse sera. Again cytotoxicity was asso-
ciated with the slow fraction. 
Fab- and Fc:fragments 
Fab- and Fe-fragments can be obtained by digesting y-immunoglobulins with 
proteolytic enzymes like papain. The antigen binding capacity is located on 
the Fab-fragment. The Fc-fragment contains the structures responsible for 
complement fixation. The Fab- and Fc-fragments of they-globulins have been 
investigated with respect to their enhancing effect. 
Chard e.a. [58] induced enhancement of EL,-leukemia in mice by Fab-
preparations, which also inhibited the cytotoxic effect of antibodies in vitro. 
These investigators used a cell type, which is unique in enhancement experi-
ments, since cells of normal or neoplastic lymphoid tissues are highly sensitive 
to cytotoxic antibodies. Furthermore, Broder and Whitehouse [ 41] showed 
that the growth of a mouse Ehrlich ascites tumor in guinea pigs was inhibited, 
when incubated with specific heterologous y2-immunoglobulins and enhanced 
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with the F(ab)z-fragment of the same serum. The Fc-fragment of an otherwise 
enhancing serum was also ineffective in the experiments of Tao and Uhr [274]. 
The effectiveness ofF(ab)z-fragment in the enhancement of renal allografts in 
rats has recently been demonstrated [240a]. Hence the Fab-fragments seem 
to be responsible for the enhancing effect, which might be related to the fact 
that they contain the combining sites for antigen. 
According to these findings the effect might take place at the peripheral 
level by binding to the antigens and not through a direct effect on the antigen-
sensitive cells. By binding to the antigen the Fab-fragments may mask its 
antigenic character. 
In contrast with such reasoning are the results of Sinclair e.a. [243], who 
demonstrated that F(ab)z-antibody alone was much less effective than whole 
antibody in inhibiting the primary hemolysin response to sheep erythrocytes. 
Other investigators [96, 129, 272, 273] found evidence for an effect of the Fc-
fragment in enhancement, which is a rather unexpected finding, for the 
Fc-fragment represents the receptor site for complement fixation and thus is 
essential for a cytotoxic effect. All these contradictory results obviously did 
not lead to a better understanding of the mechanism of immunological en-
hancement. 
2- Mechanism. 
The paradoxical influence of antiserum, namely the protective effect of cer-
tain humoral antibodies, instead of their participation in rejection, is still not 
well understood. 
Several hypotheses are proposed for the mechanism by which pre-existing 
or passively transferred antibody suppresses the immediate and/or delayed 
hypersensitivity. The early theories stem from the time that enhancement 
was only elicited with tumors. 
a. Physiological alteration qf the graft 
One of Kaliss' first hypotheses involved a non-immunological change of the 
tumor graft, that allows it to survive despite a hostile response of the host 
[140, 3]. 
b. lmmunoselection 
By immunoselection those cells that are more compatible with the host are 
allowed to survive, whereas the other cells are killed by specific antibodies. 
These two theories are now mostly abandoned. The hypotheses which are 
currently under investigation, will be discussed below. 
c. Inhibition qf the rejection reaction 
Immune inhibition can take place at the following stages (fig. 4): 
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1. The afferent arch, i.e. the process of recognition of the graft-antigens by 
host immunocytes. · 
2. The central component, which involves the stimulation of the antigen-
sensitive cells, through which an immune response arises. 
3. The efferent part, in which the graft is subjected to the attack of the cellular 
and humoral reactivity of the host. 
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Fig. 4. Simplified scheme of possible mechanisms of immunological enhancement 
It should be taken into account, that the experiments, which are cited, are all 
of a different design. Therefore opposite results do not necessarily contradict 
each other. 
Some of the findings in the literature, that contribute to the solution of the 
enigma of enhancement, will be summarized in four tables (tables 2, 3, 4, 5). 
However our interpretation of the results as presented in these tables is not 
always the same as that given by the various authors. 
I. Afferent inhibition (see table 2: afferent/central inhibition) 
Following this theory, the host is unable to recognize the allograft as foreign, 
because of a masking effect by the specific antibodies. The antigens of the graft 
are either inactivated, or their release is prevented. Thus an immune response 
will not be elicited in the host, as is also the case with central blockage of the 
immune r(.;sponse. Therefore, a differentiation between afferent and central 
inhibition could not be made in the various experiments (table 2). 
The absence or depression of the immune reaction during enhancement has 
been described by several authors. Snell [251] and Me Kenzie [175] reported 
a depression of immune reactivity of the draining lymphe nodes. Tagasuki 
[272, 273] noted the absence oflymphocytosis in enhanced mice. In addition, a 
delay in humoral response has also been observed [126, 189, 194, 251]. The 
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Table 2. Evidence for an afferent and/or central blockage of the immune response by 
enhancing antibodies 
Afferent- Central 
authors year model graft findings mechanism 
Snell '56 mouse allografts tumor rejection instead of enhancement afferent + 
by addition of donor lympho- central + 
cytes to the tumor graft efferent 
Mitchison '55 mouse allografts tumor abolishment of enhancement by afferent + 
'56 adoptive transfer of immunity central + 
MOller '63 efferent 
Billingham '56 
Hutchin '67 mouse allografts tumor slower rise ofhaemagglutinating afferent + 
MOller '63 titers during enhancement central + 
MOller '64 efferent 
Snell '60 
Snell '60 mouse allografts tumor depression of cellular immunity afferent + 
of the draining lymphe nodes by central + 
the addition of anti donor serum efferent 
to the tumor cell inoculum 
Takasugi '69 mouse allografts tumor no lymphocytosis during afferent + 
Bloom '70 enhancement central + 
efferent 
McKenzie '70 mouse allografts skin draining lymphe nodes from afferent + 
enhanced mice show less central + 
reactivity efferent 
absence of an adequate cellular response seems to be responsible for the oc-
currence of enhancement in these experiments. Consequently enhancement 
might be abolished by restoring a normal immune response. Indeed, enhance-
ment of tumor grafts in mice did not occur, when the tumor cells were mixed 
with lymphocytes from the same donor strain [250]. Apparently the anti-
genic strength of the lymphocytes had broken through the masking effect of the 
enhancing antibodies. Enhancement of tumor grafts could also be abolished 
by adoptive transfer of immunity to the enhanced mice [22, 133, 142, 184, 188]. 
This excludes the presence of an efferent blockage. 
Some evidence for the existence of an afferent inhibition was provided by 
Moller [190]: Normal rejection by A.CA mice of a tumor of the (AxA.CA)F1 
strain did not occur after in vitro incubation of tumor cells with 0.1 ml A.CA 
anti-A serum. In the enhanced mice the antibody response was delayed for 
5 days. Apparently, "coating" of the tumor cells with antibodies induced 
enhancement and delayed the humoral response. This suggests an inhibition 
at the afferent leveL Yet an efferent blockage could not be excluded, as an 
immune reaction did finally occur. 
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In contradiction to a purely afferent blockage of tbe immune response is the 
immunosuppressive effect of antibody injections 6--8 days (71, 272, 273] or 
lO days [140] after the administration of tbe antigen. Such a time interval is 
-according to several autbors [84, 164, 181]- sufficient to initiate an immune 
response. In other words, at that time the immune response is already elicited 
and the antibodies can only counteract its effect at the central or efferent leveL 
2. Central blockage of the immune response (table 3) 
Central blockage may involve the blockage of either tbe processing of antigens 
by macrophages, the transmittance of antigenic information to the antigen 
sentitive cell, or the transformation of tbe immunocompetent cells (x-cells) 
into sensitized y-cells and antibody producing z-cells. Following this theory, 
inhibition of the host's immune mechanism occurs at tbe central level by anti-
bodies, which are raised in the strain of the host and directed against tbe 
donor. This suggests a feed-back mechanism. The immune response is blocked 
by the very antibodies tbat were produced during this response. 
Table 3. Evidence for a central blockage of the immrme response by enhancing antibodies 
Central 
authors 
Batchelor 
Gorer 
Haughton 
Hutchin 
Amos 
year model graft findings mechanism 
'62 
'61 
'69 
'67 
'70 
mouse allografts tumor very small amounts of antiserum afferent -
can produce enhancement central* ± 
efferent -
mouse allografts tumor immunological reactivity of afferent 
immune lymphoid cells was lost central + 
after Contact with antibody efferent 
coated tumor cells 
* ±: no definite proof 
In most experiments tbe existence of a pure central blockage could not be 
adequately shown. Whereas a central inhibition could not be excluded in the 
experiments favouring a blockage at the afferent level, a differentiation between 
an efferent and central mechanism was often not possible either (table 4). In 
vitro and in vivo experiments, in which the inhibition of tumor growth by 
immune lymphoid cells could be prevented by antibodies, were suggestive 
of a blockage at tbe central or efferent level [2, 14, 126, 298, 299]. Recently 
Amos [2] introduced a variant of this so-called Winn-assay. He showed tbat 
mouse lymphoid cells, after incubation witb enhancing antibodies, main-
tained a normal function. However, when instead of antibodies, antibody-
coated tumor cells were incubated with the lymphoid cells, no immunologic 
activity was left in tbe lymphoid cells after separation from tbe coated tumor 
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Table 4. Evidence for a central and efferent blockage of the immune response by enhancing 
antibodies 
Central-Efferent 
authors year model graft findings mechanism 
Takasugi '69 mouse allografts tumor Antidonor serum still active when afferent 
Kaliss '58 injected 6-10 days after grafting. central + 
efferent + 
Amos '70 mouse allografts tumor Not any inhibition of tumor afferent 
Batchelor '62 growth by immune lymphoid central*± 
Hut chin '67 cells, when anti-donor serum is efferent + 
MOller '63 added to a mi:...:ture of graft cells 
and immrme lymphoid cells. 
HellstrOm '70 human tumor- mela- Prevention of destruction of afferent -
bearers noma tumor cells by immune lymphoid central*± 
cells in vitro, by addition of efferent + 
antiserum of tumor bearers. 
Moller '63 mouse allografts tumor Enhancement of tumor cells, afferent 
coated with antibodies, in central*± 
immunized recipients. efferent + 
• ± : no definite proof 
cells. An injection of incubated lymphoid cells together with fresh tumor cells 
even resulted in enhancement. The author proposed that an immunosuppres-
sive substance (I.S.S.) may be released from either the antibody-coated tumor 
cells, or the lymphoid cells after their exposure to the antibody-coated cells. 
Yet antibodies might have attached to the lymphoid cells during the incu-
bation with the antibody-coated tumor cells. 
Takasugi and Hildemann [272, 273] offered some interesting data, which 
suggests an impaired immunity during enhancement in mice. The Sarcoma I 
tumor from the A strain was tested in A.BY hosts. Hyperimmune A.BY anti 
Sa I serum induced progressive growth of the tumor. The lymphocytosis 
occurring during the normal rejection of the tumor grafts was absent in mice 
displaying enhanced tumor growth, suggesting a central or afferent inhibition 
of the immune reaction. Yet it is questionable whether a depression at the 
central level reveals itself specifically by the abscence of lymphocytosis. Sup-
pression of lymphocytosis could still be achieved by administration of en-
hancing antibodies on the 6th day after transplantation but not by surgical 
removal of the tumor at that time. The authors therefore strongly favoured 
the occurrence of a central blockage. However, the tumor cells could already 
have dispersed into the circulation or locallymphe nodes during the 6 days after 
inoculation. In such a way sensitization of the host might have continued after 
removal of the tumor. Thus an afferent inhibition in the enhanced mice could 
not convincingly be excluded. 
An argument against a peripheral effect is the observation that very small 
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amounts of antibody up to 0.0005 ml, can produce enhancement [14, 67, 89, 
110, 126]. Similarly, the protection against Graft Versus Host (G.V.H.) 
disease by passively transferred anti-host antibodies, can not be easily ex-
plained by "coating" of all the cells of the host. The abscence of a G.V.H. 
reaction by passive "facilitation immunologique" was noted by Voisin [282] 
and confirmed by others [275]. Haughton [IIO] calculated that the number 
of antibody molecules necessary to cover the antigenic sites of 5 X I 08 sheep 
red blood cells (S.R.B.C.), was 100 X higher than those needed for suppression 
of the immune response. Furthermore, total antibody coating of tumors may 
be rapidly reduced by tumor cell division and Amos [2] showed that the anti-
bodies, attached to the tumor cell surface, will be detached within 6 hours at 
body temperature. 
These observations oppose an afferent and efferent, or respectively masking 
and "walling off" effect, and are in disagreement vvith the theories of MOller, 
who favoured a pure peripheral effect. This author [187, 188, 190] studied the 
different sensitivities to antibodies of various tumors as mentioned earlier in 
this chapter. He observed that large doses of antibody caused enhancement of 
some tumors and rejection of others, whereas small doses of antibody induced 
enhancement to various degrees. He related this phenomenon to the amount 
of antigenic receptors on the surface of the tumor cells. Sensitive tumors have 
many surface antigens and will be easily damaged by high antibody and com-
plement concentrations, in contrast to the resistant tumor with few antigenic 
receptors. Thus a quantitative rather than a qualitative difference seems to 
exist between sensitive and resistant cells. This concept seems to be discon-
cordant with the finding that it is relatively difficult to enhance leukemia's, 
which consist of cells known to be highly sensitive to cytotoxic antibodies. If 
enhancement depended on the appropriate coating of tumor cells, enhancement 
ofleukemia's should also be possible. Interestingly enhancement ofleukemia's 
has indeed been reported in the last decade [31, 58, 188]. 
Suppression of the cellular response has been noted with antigens other than 
those provided by skin, tumor- or vascularized-grafts. 
The first report about inhibition of delayed hypersensitivity came from 
Crowle and Hu [67]. Antiserum from guinea pigs or mice, hypersensitized to 
chicken ovalbumin, suppressed the immediate and delayed hypersensitivity 
reactions to the ovalbumin in mice. Rowley e.a. [228], studying antibody 
mediated unresponsiveness with sheep red blood cells, also claimed to have 
some evidence for the depression of the cellular response by antiserum [227]. 
In contrast, several investigators demonstrated a normal capacity of anti-
serum treated lymphoid cells to produce antibodies, when transferred to 
irradiated or normal isologous mice [181, 191, 233, 292]. 
Evidence that enhancing antibodies can have some biological impact on 
lymphoid cells was provided by Greenberg and Uhr [96]. Passively transferred 
33 
Table 5. Evidence for an efferent blockage of the immune response by enhancing antibodies 
Efferent 
authors year model graft findings mechanism 
Cepellini '70 human allografts skin Enhancement of grafts by in vitro afferent 
·Moller '64 mouse allografts tumor incubation with antiserum. central 
Halasz '65 rabbit allografts skin Normal rejection of non- efferent + 
incubated graft in the same 
recipient. 
HellstrOm '71 human tumor- In vitro abolishment of cell medi- afferent 
bearers ated immunity of the patient by central 
incubation of tumor cells and the efferent + 
serum of the patient. 
Chancier '67 mouse allograft tumor Adoptive transfer of immunity afferent 
by cells from mice exhibiting central 
enhancement. efferent + 
Berne '65 mouse allograft tumor Enhancement of tumor graft with afferent 
Haskova '62 skin normal rejection of skin graft. central 
efferent*± 
Morris '70 rat allografts kidney Lymphocytes from enhanced rat afferent ± 
responded normally in M.L.C .. central 
efferent + 
• ±: no definite proof 
antibodies stimulated the protein synthesis in lymphoid organs of immunized 
rats, measured by 14C~leucine incorporation. A correlation however between 
this effect and immunosuppression could not be shown. 
3. Efferent blockage (table 5) 
Following this theory, the graft antigens are not destroyed in spite of a normal 
immune reaction. The cell surface is coated by specific antibodies, in such a way 
that a protective effect at the target-cell level is exerted. Moller [188, 187] 
arrived at this conclusion by the finding that enhancement of tumors could be 
passively induced in previously sensitized animals. Yet a central inhibition 
was not excluded in these studies. 
Conclusive evidence for the existence of a block at the efferent level was 
provided by several authors [55, 99, 196, 1!2, 115], by in vitro incubation of the 
graft with antibodies. They demonstrated in different experimental models the 
presence of a normally functioning immune apparatus during enhancement. 
Grafts, that were incubated in vitro with specific antibodies enjoyed a pro-
longed survival time in untreated recipients, whereas a simultaneously trans-
planted non-incubated graft from the same donor was normally rejected. 
Moller [106] showed this with tumor grafts in mice. Cepellini [55] obtained 
in one case prolongation of human skin graft survival in an A.B.O. incompa-
tible but H.L.A. identical situation, by in vitro incubation of a skin graft with 
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antiserum, whereas the simultaneously grafted control skin graft from the 
same donor was normally rejected. Halasz [99] perfused one ear of a rabbit 
with homologous antiserum. Skin grafts from the perfused ear and the other 
ear of the same rabbit were simultaneously transplanted to another rabbit. 
Skin grafts from the perfused ear survived significantly longer than those 
from the non-perfused ear. 
Hellstrom e.a. [112, 115] noted in man the destructive effect oflymphocytes 
from tumor bearing donors on plated tumor cells in an in vitro colony in-
hibition test. Incubation of the tumor cells with serum of the patient abolished 
the cell mediated immunity of the lymphocytes in vitro. The factors in the 
serum that are responsible for this blocking effect may very well be 7S-
immunoglobulins and operate at the efferent level. Thus all these experiments 
provide strong evidence for protection by specific antibodies of tumor- and 
skin grafts in mice, rabbits and man. 
An efferent blockage was less convincingly demonstrated in a few other ex-
periments. Lymphoid cells from enhanced animals were shown to be im-
munologically active: adoptive transfer of immunity by cells from mice ex-
hibiting enhancement was demonstrated by Chantler [57]. Lymphocytes from 
enhanced rats responded normally in the Mixed Lymphocyte Culture (M.L.C.) 
[20 1]. A normal immune response during enhancement has also been suggested 
for mice that displayed enhancement of tumors concomitantly with a normal 
rejection of skin grafts [108, 21]. However, different grafts were compared in 
these experiments. 
In conclusion, a general agreement has not been reached about the mechanism 
of enhancement, in the sense that it has been difficult to demonstrate a block-
age of the immune response at one single level. Most convincing in this respect 
were the findings of Moller [196], Halasz [99] and Cepellini [55], which seem 
to provide direct evidence for an rfferent inhibition. 
3. Enhancement of normal tissues 
Skin grafts 
Tumors were mostly used for the study of enhancement. A striking difference 
exists in the tendency of skin and of tumor grafts to undergo enhancement. 
Several investigators attempted to obtain prolongation of skin allograft survival 
by active or passive enhancement, but only a few were slightly successful. 
Active enhancement of mouse skin allografts has been reported by Billingham 
e.a. [22]. Pretreated A mice tolerated a CBA skin graft 4.8. days longer than 
the controls. Brent and Medawar [32] noticed a slight increase in skin graft 
survival by passive transfer of serum across the H2-locus in mice, judged by 
six-day epithelial survival scores. 
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Moller [191] reported passive enhancement of a mouse skin graft of 1.5 days, 
when donor and recipient differed at H2- plus non H2-loci, and 2.8 days, when 
the histo-incompatibility consisted of the H2-locus only. A similarly slight 
passive enhancement of mouse skin grafts was obtained by Kodama e.a. [155] 
and Chutna [60]. Passive enhancement of skin grafts has also been obtained 
in other species, like rats [65, 119, 301, 302], guinea pigs [206], rabbits [99, 260] 
and man [55]. A significant prolongation of about four days was reported by 
Heslop [119] in rats. However, only a weak histocompatibility difference 
existed in this host-donor combination. Significant results were obtained by 
Zimmerman and Feldman [301, 302] with a pronounced prolongation of 
rat skin allograft survival in more than 50% of neonatal recipients. One must 
realise though, that immature rats were used in these experiments, which 
facilitated an inhibition of the immune reaction [120]. Also in non inbred 
guinea pigs [206] and rabbits [99, 260] a slight passive enhancement of skin 
allografts could be obtained. Finally, Cepellini [55] described one case of 
enhancement of human skin grafts as mentioned previously (p. 00). By passive 
immunization in an HLA-identical but ABO incompatible combination, a 
skin graft survived 9 days longer than a control graft. 
An explanation has not been found yet for the resistance of skin grafts to 
enhancement. For a strong enhancement, the antibodies should be directed 
against all the antigens of the graft [71, 189, 192]. The antisera, used in the 
experiments with skin grafts, in general raised by injections of spleen cells 
and/or lymphocytes, did not meet these requirements, for tissue specific 
antigens probably do exist (30, Ill, 242). Most experiments on enhancement 
of tumor tissue on the other hand, were indeed performed with anti-tumor 
sera. 
If this conception is valid, enhancing sera should be raised by immunization 
with the specific graft-tissue antigens although lymphocytes are present in 
the epidermis [4]. In this respect, the experiments of Benko e.a. [19] should be 
mentioned. They produced a rabbit anti-rat skin serum, which as they claimed, 
did contain antibody against a skin specific antigen, which was not present in 
the rat plasma. This serum induced an unresponsiveness towards allogenic 
rat skin grafts. Similarly N elken and Cohen [205] reported prolonged survival 
of rat skin allografts after incubation with rabbit and chicken anti-rat skin sera. 
However, it should be born in mind, that such sera can also be regarded as 
unconventional antilymphocyte sera and the observed effect could be due to 
that property. 
Renal allografts [202, 203, 220] 
Much better results have been obtained with the enhancement of renal allo-
grafts (table 6). One of the· first reports came from Halasz [101]. Dog kidney 
allografts survived significantly longer after pretreatment of the recipient with 
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Table 6. Enhancement of renal allografts 
en- M.S.T. M.S.T. 
active/ hance- controls C..'\..'J>Crimental 
author year passive m=t model group 
Halasz '64 active ± canine allografts 8.1 29 
Wilson '69 active ± canine allografts 9 144 
Wilson '70 active ± canine allografts 9.4 44 
Stuart '68 active+ + rat-AgB locus >100 
passive 
French '69 passive + rat 8.5 > 120 
Morris '70 passive + rat-AgB locus 
-
Ockner '70 active ± rat-AgB locus > 120 
Zimmerman '70 active ± rat-AgB locus 
Marquet '70 active ± rat-AgB locus 12 100 
Batchelor '70 passive ± human-By26 locus > 90 
±: no definite proof for enhancement 
subcutaneous injections of 2 ml donor blood. A differentiation between en-
hancement or tolerance as the underlying mechanism was not attempted. 
Later donor blood has been successfully used as pretreatment for porcine liver 
allografts [46] and renal allografts in rats [167]. Marquet [176] obtained pro-
longation of renal graft survivals in rats up to 350 days and permanent ac-
ceptance of heart allografts. 
Prolonged canine renal allograft survival by pretreatment with donor spleen 
cells has also been reported by Wilson e.a. [296, 297]. 
Recently very extended survivals were obtained across the major AgE-locus 
in rats, by pretreatment with either bone marrow cells [211, 212] or spleen 
cell fractions [30 I, 302]. Definite proof for enhancement has however not been 
provided in either of these studies on active enhancement. It remains possible 
that tolerance is the cause of the extension of graft survival in these experi-
ments. 
The first to describe the passive transfer of enhancement by serum with 
renal allografts was Stuart [269, 270]. He obtained a long survival of rat 
kidney allografts by injections with donor antigens, anti-donor serum, or both, 
across the strong AgE-locus in rats. In the same experimental model indefinite 
survival was recently described by Morris e. a. [20 1]. French and Batchelor [87] 
induced indefinite survival of (August xAS) kidney allografts in AS rats by 
passive transfer of anti-donor serum. Antibody titers were shown in the rats 
displaying enhancement. Apparently, sensitization of the recipients had also 
occurred. 
Batchelor [17] even applied the principle of passive enhancement to a human 
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kidney transplantation. The antiserum was raised in the father of the patient 
by injections with cells of the donor "casu quo" the mother. Fab-fragments of 
this serum were injected into the recipient, who received a kidney from the 
mother, which only involved one HLA-incompatibility. The kidney functioned 
well, but a difficulty in the interpretation of his results arises from the use of 
immunosuppressive drugs postoperatively. 
Interestingly, in a few cases a rat skin graft transplanted tp a recipient 
tolerating a kidney graft from the same donor strain, was rejected within 
normal time [201, 211, 212]. Yet, in the case of enhancement, one would 
expect either acceptance of a second graft or a concomitant rejection of skin 
and kidney, unless enhancement is mediated either by protection of the antigens 
at the efferent level or by organ specific antibodies. It might also be possible 
that enhancement is more easily induced with vascular grafts. 
Such a difference in rejection patterns between skin and kidney grafts in 
rats has been reported previously in cases with weaker genetic disparities. 
White and Hildemann [289, 290, 291] showed this in the Fischer-Lewis 
combination. Without any treatment, kidneys of the Fischer strain were 
accepted by Lewis rats for as long as 32 weeks, whereas Fischer skin grafts 
were rejected in a median survival time of 10-13 days. This phenomenon, 
as Sakai [235] pointed out, occurs in many weak rat strain combinations. Self 
enhancement as proposed by White and Hildemann, is not an obvious explana-
tion, for enhancing antibodies are specifically directed against all the donor 
antigens and hence also against the skin. Adaption or a lesser vulnerability of 
the kidney grafts fits in better with the different findings in these experiments. 
A stronger sensitization with skin grafts than with vascularized organs may well 
play a role. This difference is due to the fact that lymphatic vessels are more 
important for the sensitization process than blood vascular channels [12]. 
Similar results have been reported for heart [ll] and liver grafts [46]. 
Thus one should not rely too much on the results obtained with vascular 
grafts across weak histocompatibility barriers as these results can be due to 
several other mechanisms rather than enhancement. In particular they should 
not lead to the conclusion that clinical application of enhancement is justi-
fied at this time. 
4. Antibody-n1ediated hUID.oral unresponsiveness 
The reason for discussing antibody mediated humoral unresponsiveness in this 
same chapter, is its possible relation with enhancement. It comprises the de-
pressing effect of passively administered specific antibodies on the humoral 
response to simultaneously injected antigens. In the beginning of this century, 
studies directed at the prevention of infectious diseases revealed that a mixture 
of toxoid and excess antibodies did not result in active immunity [248]. It was 
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not until 50 years later that this phenomenon was studied more extensively 
with various antigens e.g. viruses, bacteria, red cells, toxins and proteins. Uhr 
and Moller wrote an excellent review about this subject [281]. 
The suppression of the humoral response was either assessed by the level of 
antibody titers in the serum or the number of antibody producing cells in the 
spleen. The two tests give information about the humoral immunity and will 
be discussed concurrently. The plaque forming cell technique of J erne and Nordin 
[131] enables the enumeration of antibody producing cells, which form he-
molytic plaques in a layer of sheep red blood cells (S.R.B.C.). These plaque 
forming cells (P.F.C.) appear after a latent period of 24 hours and reach their 
maximum 4-5 days after immunization [ 4 7]. Using this test, the effect of 
anti-S.R.B.C. serum in mice [117, 196, 200, 193, 192, 293] and rats [227, 228] 
was thoroughly studied. Much of the information about antibody mediated 
humoral unresponsiveness arose from these studies. It was established by many 
investigators that the suppressive effect of antibodies is specific for. the antigens 
concerned [20, 42, 188, 229, 278, 291, 291]. 
One of the first investigations about the paradoxical depression of humoral 
reaction by its own products, came from Uhr and Baumann [278, 279] in 
their experiments. Excess antibody was favourable for the occurrence of sup-
pression of the humoral antibody response. Injections of diphtheria toxoid 
together with antitoxin excess in rabbits, rats or guinea pigs did not provoke 
the expected primary antitoxin response. The authors suggested a feed-back 
mechanism effectuated by the binding of antibodies to the antigens, which in 
such way became inactivated. 
Another hypothesis has been proposed by Hanna eta! [103] i.e.: antibodies 
block the conversion of antigen sensitive x-cells to sensitized y-cells and to 
antibody producing z-cells, by covering of the antigens. By this blockage a 
maturation arrest occurs in the A)'Z-transformation. This induces an expansion 
of they-cell compartment, that is responsible for the secondary response [100, 
I 02]. This theory is based on the assumption that antibody formation and 
immunological memory are dependent upon the continuous presence of anti-
gens [280, 293, 294]. 
The question arises whether this feed-back mechanism also occurs in a more 
physiological situation. Morris and Moller [200] showed that not only artifici-
ally administered antibodies, but also endogenously formed antibodies can 
induce humoral unresponsiveness. In their experimental model immune or 
hyperimmune mouse spleen cells adoptively transferred to syngeneic recipients, 
suppressed the l9S-synthesis to S.R.B.C. as measured by P.F.C. The decrease 
in IgM-formation by 7S-antibodies has also been demonstrated by some other 
investigators [193, 234, 280]. It appears that a prevention of excess antibody 
formation is thus part of a more general homeostatic mechanism. 
Initially it seemed that only IgG was responsible for this phenomenon [84, 
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67], but various investigators have subsequently demonstrated tbe effectiveness 
oflgM [193, 227, 293]. 
IgG not only seems to be more effective in the induction of humoral un-
responsiveness, but moreover sensitized 7S forming cells are more resistant to 
inhibition [34, 193, 234]. The development of P.F.C. is most easily inhibited 
by antibodies administered before or during the induction of antibody syn-
thesis and is not affected during a second set response. Yet, antibody mediated 
suppression of the 7S-response is possible. Even long after the peak of IgG-
production, its inhibition could be induced by special batches of IgG, obtained 
late after immunization [294]. 7S-antibodies seem to be more effective 
in inhibiting antibody formation after an increasing number of immu-
nizations [71, 84, 237], indicating their qualitative change with time [294]. 
These findings suggest a relation between the affinity of antibodies for anti-
genic determinants, - which occurs late in immunization - [79, 246] and tbe 
capacity to inhibit the humoral immune response. This was confirmed by 
Walker and Siskind [237], who noted a much better suppression of high 
affinity antibodies than of low affinity antibodies. The antibodies however 
have to compete with preformed antibody present on the surface of certain 
antigen sensitive cells [74, 295]. The existence of the antibody-like receptors 
for antigens on lymphoid cells was demonstrated by the selective binding of 
immune cells in glass bead columns, which were coated witb specific anti-
gens [295]. 
The antigen combining site of these cell-associated antibodies seems to be 
similar to that of tbe antibodies which will finally be produced by those cells 
after immunization. An increase in affinity for antigens with time also occurs 
with these cell-associated antigen-specific receptors. Thus only high affinity 
antibodies can succesfully compete with high affinity cell-associated antigen-
specific receptors and this circle of events may well constitute the feed-back 
mechanism under discussion. Consequently, the suppression of a secondary 
immune response by antibodies will be much more difficult, because of tbe 
high avidity of the competing receptor sites of the sensitized cells for antigen 
[200, 227, 277, 292]. 
Another explanation for tbe mechanism of humoral unresponsiveness is 
put forward by some investigators, who suggest a direct effect of antibodies on 
the immune competent cells [83, 96, 227, 228, 244]. In addition to humoral 
unresponsiveness, suppression of the cellular response is also reported [3, 67, 
68]. Delayed type hypersensitivity to S.R.B.C. in rats was partially abolished 
by either active or passive immunization, but completely by a combination of 
antigen and antibody injections [7, 8]. The inhibition of a cellular response is 
of course of importance for eventual clinical application of tbis phenomenon. 
In conclusion, the bulk of the experimental data suggests that an important 
step in the suppression of the humoral response is the interaction of antigens 
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and antibody. This conclusion is substantiated by tbe specificity of tbe un-
responsiveness and tbe effectiveness of antibodies with high affinity for anti-
genic determinants. Apparently, high affinity antibodies preferentially bind 
with antigen, in competition with those immunocompetent cells that contain 
receptors on the cell surface, which have a structure similar to that of tbe anti-
bodies. The significance of this feed-back mechanism for the organism as a 
whole is still not well understood, but it seems clear that antibodies play an 
important role in the regulation of the antibody formation. A similar mechanism 
may be effective in the prevention of Rh immunity by means of anti-Rh 
antibodies [62]. 
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CHAPTER IV 
ACTIVE ENHANCEMENT OF SKIN ALLOGRAFTS 
IN MICE 
1. Introduction 
Enhancement is, as Kaliss showed [132], mediated by specific antibodies, 
directed against the graft and has been thought to be completely different 
from tolerance [160, 178, 182]. Efforts to obtain enhancement of skin grafts 
were only slightly successful [22, 34, 60, 119]. On the other hand much of the 
work on tolerance has been successfully performed with skin grafts. Pre-
treatment of adult recipients with a variety of donor tissues resulted in specific 
graft acceptance, which was mostly ascribed to tolerance [72, 178]. Either 
homogenates, cell fractions, extracts or viable cells were used [60, 169, 170, 
178] via intraperitoneal (i.p.) or intravenous (i.v.) injections [22, 120, 240b]. 
Prolonged survival of skin allografts in adult mice has been reported across 
the strong H2-locus by injections of high doses of donor-spleen cells [22, 169, 
240b, 34]. Halasz e.a. [99] demonstrated prolonged survival of kidney-
allografts in dogs by subcutaneous (s.c.) injections of donor blood prior to 
transplantation. 
This immunological unresponsiveness is mostly thought to be induced by 
tolerance [178]. However, partial and total immunological unresponsiveness 
towards a graft after pretratment with donor antigens could be caused by 
either active enhancement or tolerance. Indeed a few authors reported passive 
transfer of the immunological unresponsiveness by serum which strongly 
suggests that enhancement is responsible for the effect [60, 20]. 
The purpose of the current experiments was to achieve more pronounced 
enhancement of skin grafts in mice in view of the mediocre results obtained 
previously with enhancement of skin grafts. Skin grafting is an easy and fast 
procedure and should thus be an advantageous model for the study of en-
hancement. 
To facilitate the attainment of enhancement a model was designed in which 
the host differed from the donor at one single histocompatibility antigen of the 
strong H2-locus. This difference was strong enough to induce a fast rejection in 
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untreated hosts. B.AFl (31-) mice (Cs,BL/GJXA/JaxFl-hybrids) were injected 
with viable or frozen-thawed B10D2 (31 +) cells as a pretreatment for a B10.D2 
skin graft. In this combination a monospecific histo-incompatibility exists, 
constituting a so-called co-isogenic combination. The B10.D2 mice are isogenic 
with the B.AF mice except for the 31-specificity of the H2-locus (table l). 
Two major subdivisions of the H2-region can be discerned in mice. These 
are the "D end" and the "K end" respectively [275b]. The 31-specificity is 
following Snell e. a. [258b J a "private" H2-specificity, located at the K end of 
the H2 -chromosomal region. 
2. Material and m.ethods 
Animals 
B•AF1 (31-) mice were recipients of cells or skin from B10.D2jnew Sn (31+) 
female mice. This is a coisogenic combination. Before applying a B10.D2 female 
skin graft, frozen-thawed or viable female B10.D2 tissue was injected s.c., i.p or 
i.v. into B.AFl mice. The B.AFl mice were divided into different groups. Each 
member of a group was treated with cells from the same suspension. All the 
mice in these and the following experiments were more than seven weeks old 
and purchased from the Jackson Laboratory, Bar Harbor, Maine. Females 
and males were used separately. 
Preparation of the cell suspension 
Viable cells. For the preparation of viable cells, spleens and lymphe nodes 
were collected in medium 199 and then gently pressed through a stainless 
steel mesh. Cell counts were performed in a haemocytometer and viability 
determined by exclusion of Trypan blue. 
Non-viable suspensions. Spleens and lymphe nodes in most cases mi.xed with 
livers, were collected in medium 199, pressed through a stainless steel mesh 
and frozen in dry ice with alcohoL 
After freezing and thawing three times, viable cells could not be detected. 
After spinning down, a 20% solution in saline was made by mi.xing in a blender. 
To prevent intravascular clotting, 125 U.S.P. units sodium heparin were 
added to 1 ml of the suspension. The 20% solution was injected once a week, 
either slowly intravenously into the tail vein or s.c. or i.p. Of the frozen-thawed 
suspension 0.25 ml was used per injection unless otherwise stated. The test-skin 
grafts were applied one day after the last injection. 
Skin grafting 
Skin grafts were performed following the technique of Billingham and Meda-
war [24]. The graft bed was prepared with curved scissors, leaving the panni-
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culus carnosus muscle and the vascular fascial planes immediately overlying 
the panniculus intact. Grafts of 1.5 X 1.5 em were placed on the back of the 
recipient, then covered with vaseline petrolatum gauze and held in place by 
plaster bandage. Plasters were removed on the 8th day and the grafts inspected 
every other day by macroscopical examination. Rejection was characterized 
by complete destruction of epithelial surface. 
Antiserum 
Serum used for passive transfer was collected from B,AF 1 male mice, which had 
been treated with three i.v. injections of frozen-thawed B10.D2 tissue. These 
mice were bled one day after the last injection from the sinus cavernosus of the 
eye. The blood was kept at room temperature until clotting occurred and 
afterwards at +4 oc overnight for further contraction of the clot. 
Statistics 
Statistical significance of the results was tested with methods of Student Welch 
and Wilcoxon. M.S.T. denotes Median Survival Time and x stands for the 
Mean Survival Time. The two tests had to be used together, for the distri-
bution of the data was not always suited for the application of one single test. 
3. Results 
Controls 
B1o.D2 female skin grafts were rejected in 8 to 12 days (M.S.T. 9 days: s.d. 1.32) 
by 45 B,AF 1 females. However, 24 B,AF1 males rejected the B1o.D2 skin grafts 
later (M.S.T. 12 days; s.d. 1.21). Thus the difference in immune response 
between males and females manifested itself in these experiments in a different 
rejection period of skin grafts. 
Subsequently the effect of pretreatment with injections ofB1o.D2 cells on the 
survival of B1o.D2 skin grafts was studied. The donor cells consisted of either 
frozen-thawed or viable cells. 
I. FROZEN-THAWED B10.D2 TISSUE 
The results of injections with spleen, lymphe node and liver cells are described 
under A. The experimental groups resorting to B only received injections of 
cells from spleen and lymphe nodes. 
A. SPLEEN, LYMPHE NODES AND LIVER 
The bulk of the suspension used in these experiments was formed by liver 
cells. 
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Route of injection 
Four subcutaneous, intraperitoneal or intravenous injections of the same cell 
suspension in 30 BsAF, mice, resulted in a prolongation of the survival time 
of a subsequent B10.D2 skin graft of respectively 2.5, 6 and 8 days (fig. 5). Thus 
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Fig. 5. B12 -D2 skin grafts transplanted to B6AF1~ after pretreatment vvith 4 injections of 
frozen-thawed B10 • D 2 liver cells. spleen cells and lymphocytes at weekly intervals. 
no sensitization was obtained with these injections. The prolongation of graft 
survival was most strongly manifested with i.v. injections and least obviously 
with s.c. injection. Consequently only i.p. and i.v. injections were used in the 
experiments. 
Number ofi.p. and i.v. injections in BsAF,females (table 7) 
a. Intraperitoneal injections 
The B10.D2 skin grafts did not survive for a longer time after pretreatment with 
I, 4 or 5 i.p. injections. Only one group, which received 3 i.p. injections with 
Freund's adjuvant added, rejected a B,o.Dz skin significantly later. 
b. Intravenous injections 
One or two injections did not lead to an extension of graft survival. Three 
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Table 7. Female B6AF 1 mice transplanted with~ B10 ·D: grafts. Pretreatment with a different 
number of injections at weekly intervals of frozen-thawed~ B10 • D 2 liver cells, spleen 
cells and lymphocytes, following various routes. 
number of 
route injections n M.S.T. s.d. Pstudent P Wilcoxon 
0 45 9 1.32 
i.p. 1 7 9 1.51 0.80-0.40 < 0.4 
3* 9 18 3.08 < 0.0005 < 0.000003 
4 8 9 0.99 0.50-0.25 < 0.9 
5 5 8 1.52 0.30-0.15 
i.v. 10 9 0.98 0.50-0.25 
1** 5 8 1.73 0.60-0.30 
2 7 9 1.62 LO 
3 7 18 59.14 
3 9 12 1.98 < 0.005 < 0.006 
3 9 12 2.38 < 0.005 < 0.005 
4 10 12 1.95 < 0.005 < 0.008 
5 10 14 5.16 < 0.01 < 0.00004 
i.p.+i.v. 3+2 5 14 2.68 0.05-0.025 < O.Dl 
3+3 5 10 3.67 0.20-0.10 < 0.04 
3+4 5 11 2.55 0.10-0.05 < 0.05 
5+2 5 10 2.83 0.40-0.20 
* plus Freund's adjuvant 
** 0.05 rnl/injection 
injections however resulted in a significant prolongation of a subsequent skin 
graft. Two of the B,AF1 mice, that received three injections even did not reject 
the B10.Dz skin before day 135, beyond which time the grafts were not ob-
served. Four or five injections ~ere not more effective than three injections. 
c. Intraperitoneal and intravenous injections 
A combination ofi.p. and i.v. injections was also effective but not as much as 
i. v. injections alone. 
In conclusion, i.v. injections only lead to a consistent prolongation of graft 
survivaL A correlation seems to exist between the number of injections and 
the occurrence of decreased immunological responsiveness. 
i.v. injections in B6AF1 males 
A more significant prolongation was expected to occur with the use of B,AF 1 
males as recipients, because of their weaker immune response, which is supposed 
to be easier overcome. This did not happen and the results were comparable to 
those in the females (table 8). Pretreatment with 2-6 i.v. injections resulted in 
a longer survival of subsequent skin grafts. 
Time response 
As mentioned before, all mice were grafted one day after the last injection. Of 
interest i; the follow-up of the immune response of the immunized mice during 
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Table 8. Male B6AF 1 mice transplanted with B10 • D 2 skin grafts. Pretreatment with different 
numbers of i.v. injections of frozen-thawed~ B10 ·D2 liver cells, spleen cells and 
lymphocytes. 
number of 
injections n M.S.T. x s.d. P Student Pwncoxon 
0 24 12 11.6 1.21 
2 10 14 13.7 2.50 < 0.02 < 0.005 
3 lO 15.5 18.1 6.12 < 0.01 < 0.0004 
3 9 16 15.0 2.18 < 0.001 < 0.002 
3* 10 12.5 12.2 1.75 < 0.30 < 0.5 
5 10 17 16.3 2.94 < 0.0005 < 0.0002 
6 10 13.5 14.2 1.75 < 0.0005 < 0.002 
* plus Freund's adjuvant 
Table 9. B0AF1 transplanted with~ B10 ·D 2 skin grafts at varying times after the last i.v. 
injection with frozen-thawed B10 • D 2 liver cells, spleen cells and lymphocytes. 
Two groups: female and male B0AF1 recipients. 
number 
of interval 
sex injections in days* n M.S.T. x s.d. P Student Pwncoxon 
0 0 45 9 9.4 1.32 
3 l 6 ll 11.3 1.97 < 0.05 < 0.06 
3 4 6 15 15.0 3.29 < 0.01 < 0.0002 
3 ll 5 13 14.0 3.46 < 0.05 < 0.0004 
3 21 5 14 13.8 1.30 < 0.001 < 0.0003 
'i! 3 33 5 10 10.8 1.92 < 0.20 < 0.4 
3 l 5 14 16.0 5.20 < 0.05 < 0.0002 
3 5 4 10.5 10.75 0.96 < 0.10 
2 3 9 5 10 ll.O 2.0 < 0.20 < 0.25 
3 15 5 9 9.4 1.14 < 0.9 
3 25 5 14 14.0 3.39 < 0.05 < 0.001 
0 0 24 12 11.6 1.21 
3 I 7 14 14 3.41 < 0.10 < 0.02 
3 4 10 16 17.6 5.95 < O.Ql -> 0.0003 
3 22 9 14 14.1 2.26 < 0.01 < 0.008 
5 3 33 II 14 13.7 2.00 < 0.005 < 0.008 
4 l 10 11.5 11.9 2.51 < 0.70 < 0.6 
2 4 4 9 15 15.2 4.32 < 0.025 < 0.04 
4 6 6 13 13.12 2.14 < 0.20 < 0.2 
* between last injection and skin grafting 
a certain time after the last injection. This could give some information, as to 
whether enhancement or tolerance is the cause of this phenomenon [134]. 
a. Female BsAF1 mice 
Two groups were treated with 3 i.v. injections and subsequently grafted at 
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Fig. 6. B10 • D 2 skin grafts transplanted to B6AF 1 females at varying days after the third i.v. 
injection with frozen~thawed B10 ·D 2 liver, spleen and lymphocytes. 
different times after the last injection (table 9). In the first group (table 9 and 
fig. 6) the prolongation of graft survival was most significaot on the 4th day 
after the last injection and not on the 1st day. Grafting on the 21st day after the 
third inoculation resulted in a decrease in extension. The second group (table 9) 
displayed a different rejection pattern. Prolongation occurred after the first 
day with a 5i of 16 days (s.d. 5.20) followed however by a rapid decrease in 
prolongation from the 5th to 15th day. Afterwards an increase in survival time 
occurred. 
b. BsAFt males 
With two groups of BsAFt males the strongest prolongation of graft survival 
did not occur at the 1st day, but at or after the 4th day (table 9). This does 
not suggest tolerance as the cause, for in that case an immunological respon-
siveness was to be expected from the first day on. Yet a maximal humoral 
response could be expected from the 4th day on. Thus enhancement might 
be the cause of the prolongation of graft survival as immunological enhance-
ment depends on the occurrence of antibodies. 
Second set response 
In this experimental group Bw.D2 females were grafted without any pretreat-
ment and subsequently were injected with frozen thawed tissue after the re-
jection of the first graft had taken place. A second set response is characterized 
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Table 10. Survival times of second~ B10 ·D 2 skin graft on B0AF1 female mice after pretreat-
ment with i.v. and i.p. injections offrozen-thawed B10 • D 2 liver cells, spleen cells and 
lymphocytes. 
pretreatment n M.S.T. x s.d. 
0 45 9 9.4 1.32 
I skin graft 24 7 7 1.12 
I skin graft 8 8.5 8.5 0.53 
4 i.p. injections 
1 skin graft 5 13 60.4 69.05 
4 i.p. injections 
4 i.v. injections 
4 i.v. injections 5 7 9.2 3.03 
1 skin graft 
by an early and strong reaction, which is not easily overcome by the various 
immunosuppressive drugs. In these experiments a second set response could be 
abolished by i.p. and i.v. injections of frozen-thawed tissue (table !0). A sur-
prising effect appeared in a group of BsAF 1 mice, which was treated after the 
first skin graft with 4 i.p. and 4 i.v. injections B10.D2 tissue. In this group two 
of the second B10.D2 skin grafts were not rejected at the !36th day. 
B. SPLEEN AND LYMPHE NODES (table II) 
l %, !0% or 20% solutions offrozen-thawed B,o.Dz tissue oflymphe nodes and 
spleens did not produce a significant prolongation of skin graft survival when 
injected in BsAF, male mice. A slight sensitization was induced by i.p. injec-
tions. Thus the addition of liver tissue proved to be important for the achieve-
ment of immunological unresponsiveness, as injections with cells of spleens and 
lymphe nodes alone were not effective in these experiments. 
Table 11. Male B0AF 1 mice transplanted with female B10 • D 2 skin grafts, 3 days after pre-
treatment with various solutions of frozen-thawed B10 ·D2 spleen cells arid lympho-
cytes. 
route solution n M.S.T. x s.d. Pstudent Pwncoxon 
24 12 11.6 1.21 
i.v. 1% 10 12 12.3 1.77 < 0.30 
i.v. 10% 10 11 11.3 1.16 < 0.50*** 
i.v. 20% 8 13 13.5 2.27 < 0.05 < 0.17 
. * l.V. 20% 10 11 . 11.4 1.50 < 0.80*** 
i.v. 20% 10 12 12.0 2.79 < 0.70 < 0.8 
i.p. 20% 10 10 10.3 1.42 < 0.025*** 
s.c. 20% 10 10.5 10.7 1.64 < 0.20*** 
i.p. ** 20% 5 10 10.2 1.30 < 0.10 *** 
* skin grafted 1 day after last injection 
** plus Freund's adjuvant 
*** shorter survival time than controls 
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II. VIABLE B10.D2 TISSUE (table 12) 
Pretreatment with viable B10.Dzlymphe node and spleen cells also resulted in an 
inhibition of the rejection reaction when more than two injections were used. 
One injection with 1, 18 or 30 X 10• viable donor cells however resulted in an 
accelerated rejection. In contrast to the previous experiments with frozen-
thawed tissue, acceptance of skin grafts was in this experiment achieved without 
the addition of liver cells to the suspension. 
Table 12. Female B6AF 1 mice transplanted with female B10 • D: skin grafts. Pretreatment 
with i.v. injections of viable~ B10 -D2 spleen cells and lymphocytes. 
number of 
injections dose n 
0 0 45 
I X 10' 4 
18 X 10' 4 
I 30 X 10' 4 
2 18x 10' 8 
40 X 10' 
3 16 X 10' 9 
20 X 10 6 
20 X 10' 
* shorter survival 
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Fig. 7. B10 ·D2 skin grafts transplanted to B;;AF1 males. Effect of the passive transfer of anti-
B10 • D:l serum from actively enhanced B 6AF 1 mice. 
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Passive transfer of immunological unresponsiveness (fig. 7) 
The question arises whether the effect of the injections with cells from the donor 
strain was related to enhancement or to tolerance. A crucial test for enhance-
ment is its passive transfer by antibodies. Serum was collected from B6AF 1 
male mice, which were bled one day after the third injection with frozen-
thawed B10.D2 tissue. Then 0.2 ml of this serum was injected every other day 
in BsAF1 mice until the day of rejection. B1o.D2 skin grafts in these BsAF 1 mice 
enjoyed a significantly prolonged survival up to 17 days. The prolongation 
was comparable to those obtained by injections with donor celles in the 
previous experiments. 
4.. Discussion 
In the present experiments the effect of administration of donor cells prior 
to skin grafting was studied. 
A coisogenic strain combination was used, the BsAF1 (31-) mice being the 
recipients of B10.D2fnew Sn (31+) cells and tissue. B10.D2 female skin grafts 
were rejected by BsAF1 females in 9 days M.S.T. Thus the 31 specificity of the 
H2-locus expresses itself as strongly in the BsAF 1 females as the whole H2-locus. 
In males the rejection occurred at a somewhat later time. 
According to the literature multiple injections usually have been more 
effective in accomplishing graft acceptance [22, 120, 169, 240]. In these ex-
periments the number of injections also proved to be important. Significant 
prolongation only occurred after more than two i.v. injections offrozen-thawed 
or viable B1o.D2 tissue were given. However no increase in graft acceptance 
was achieved by increasing the number or dose of inoculations any further. 
Even a second set response could be abolished by i.v. and i.p. injections of 
frozen-thawed tissue. Two BoAF1 mice accepted a second B1o.D2 graft beyond 
136 days! 
Much effort was directed towards the differentiation between tolerance and 
enhancement. Tolerance has been usually established with i.v. injections of 
lymphoid cells [95, 120, 169, 178, 240]. Frozen-thawed lymphoid cells alone 
did not have any significant effect in these studies. The addition of liver cells 
was necessary for the attainment of more consistent prolongation of graft 
survival. Viable lymphoid cells however produced immunological unrespon-
siveness, when more than two injections were used. 
The skin grafts in these experiments were usually applied on the first day 
after the last injection. However a better effect was often noted on the 4th day 
after the last injection (table 9). These results cannot easily be explained by 
tolerance. On the contrary, the maximal graft acceptance seems to coincide 
with maximal antibody production, which can be expected on the fourth day. 
Enhancement then, is the most likely explanation. Repeated i.v. injections were 
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most successful, which may induce a strong antibody response, as reported by 
Leskowitz e.a. [161]. He noted that one i.v. inoculation of bovine serum al-
bumen in rabbits resulted in neither antibody formation nor delayed hyper-
sensitivity. An i.v. booster injection on the other hand induced a very good anti-
body response. 
An argument against enhancement might be the evidence that liver extracts 
have always been less effective in inducing immunity and enhancement [124, 
132, 151] than spleen cells, whereas in our experiments the presence of liver 
in the frozen-thawed suspension was prerequisite for a good effect. However, 
viable lymphoid cells were effective without the addition of liver cells. It is 
possible, that enhancement and tolerance might act together in these experi-
ments. Interesting in this respect is the finding of Dresser [73], who showed 
that the administration of CBA anti-BCG serum in EGG-tolerant CBA mice 
did not increase the mechanism of recovery from the state of paralysis, but 
instead could inhibit this recovery. 
Further proof for enhancement in these experiments are the favourable 
results with passive transfer of serum from those B6AF1 mice, which were treated 
with i.v. injections of frozen-thawed B10.D2 tissue. With this serum a significant 
prolongation of skin graft survival was obtained, which was quite comparable 
to the prolongation observed in those mice, that produced the serum. The 
immunological unresponsiveness could thus be transferred by serum. Hence 
enhancement is a likely mechanism of these phenomena. 
5. Sununary 
Active enhancement of mouse skin grafts was obtained in a coisogenic strain 
combination, where the H2-3l specificity appears to form a strong histo-
compatibility barrier. 
Pretreatment of the BsAF1 recipients with either frozen-thawed or viable 
B1o.D2 cells resulted in prolonged acceptance of skin grafts, provided that more 
than 2 injections were given. Even second skin grafts were accepted fOr a longer 
period in this experimental model. 
Proof for enhancement was provided obtaining a similar effect through 
transfer of serum and the observation that maximal graft survival occurred in 
the period of the expected maximal antibody formation. 
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CHAPTER V 
PASSIVE ENHANCEMENT OF SKIN ALLOGRAFTS 
IN MICE 
1. Introduction 
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Mter our initial success with active enhancement of skin grafts, a model was 
designed, in which passive enhancement of skin grafts could be established 
[130b]. The mechanism of enhancement can be best studied with passive en-
hancement, for tolerance may play a role in active enhancement. 
In the case of an afferent or efferent mechanism of enhancement it is im-
portant to cover all the alloantigens by specific antibodies [71, 189, 192]. 
Fortunately, greatly simplified experimental models have become available 
with the development of congenic strains of mice, which are virtually identical in 
genotype, except for an allelic difference at a single histocompatibility locus. 
Such a combination was used in these experiments, with a single histocompa-
tibility difference at the H2-locus. There are, however, many specificities in the 
H2-locus and to be able to cover all the foreign alloantigens by antibody, we 
used combinations where the recipient differed only at one H2-specificity from 
the donor, namely the 31-specificity or 32-specificity (table 1). 
2. Material and :methods 
Animals 
B.,AF1 (H2•b) mice (C57BL/eJXA/Jax F1 hybrids) were used as recipients for 
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tissue or skin ofB10.D2jnew Sn (H2ct), B1o.BR (H2"k) and (B10.D2 xB10.BR)F1 
mice. They are coisogenic for respectively the 31, the 32 specificity and 31 +32 
specificity of the H2-locus. C57BL/10 and (129 xA)F1 mice were recipients for 
B10.D2 skin grafts in order to test the specificity of the anti-31 serum. B10.D2 
mice differ from the C5,BL/10 mice at the H2-specificities 3, 4, 8, 10, 13, 31. The 
B10.D2 and (129 xA)F1 mice are apart from the H2-31 specificity also in-
compatible at non-H2-loci. 
Antiserum 
For the acquisition of hyperimmune anti-31 serum, BsAF 1 mice were re-
peatedly immunized with viable B10.D2 lymphoid cells for about four months. 
Seven to twenty days after the last i.p. injection, the mice were bled. The serum 
was pooled and stored at -20 °C. Anti-32 serum was prepared in BsAF 1 mice 
by immunizing them with C2HK (H2") lymphoid tissue and Freund's adjuvant 
for two months. The mice were bled from the retro-orbital sinus. The blood 
was kept at room temperature until clotting occurred and afterwards at -4 oc 
overnight for further contraction of the clot. 
Titers 
Cytotoxic titers up to I: 1000 were measured in the sera by McKenzie [174, 
175]. 
Preparation of the cells 
For the preparation of viable cells, spleen and lymphe nodes were collected and 
treated as described on p. 74. 
3. Results 
The B1o.Dz mice only differ from the BsAF1 mice at the 31 specificity of the 
H2-locus. Yet the B10.D2 skin graft survival times on B6AF 1 females do not 
differ considerably from those occurring across a H2-locus incompatibility 
(fig.8). 
A weaker immune response of the males became apparent in this combinac 
tion, as was shown in the previous experiment. Hence male and female mice 
were used separately in these experiments. Antiserum was injected in amounts 
of0.2 ml every other day until the day of rejection unless otherwise stated. 
Effect of multiple injections of anti-31 serum 
Serum injections of 0.2 ml every other day in 31 female- and. 20 male B6AF1 
recipients, resulted in a significant prolongation ofB1o.D2 skin graft survival time 
(fig. 8). By prolonging the survival of skin grafts, a bigger spread in survival 
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time was noted. Such a spread can be expected with the use of weak H-loci 
[121, 123]. Thus the treatment with anti-31 serum seems to reduce the strong 
H2-31-locus to a weak H-locus, by partially or temporarily eliminating the 
disparity for the 31 specificity. The magnitude of extension of graft survival by 
the anti-31 serum is similar in the female and male recipients. This is in contra-
diction to the opinion of many investigators, who claim that enhancement is 
easier procured in male recipients. 
This experiment depicted in fig. 8 shows that passive enhancement of skin 
grafts can be obtained in mice. The antisera were usually injected intra-
peritoneally. Intraperitoneal injections of anti-31 serum proved to be as 
effective as intravenous injections (table 13). 
Table 13. Effect of route of serum injections. B10 -D2 skin grafts on B6f\F1 males and females, 
treated with anti-31 serum. 
route of 
sex injection n M.S.T. x s.d. Pstudent Pwilcoxon 
~ i.p. 5 20 20.6 !.82 0.15-0.30 < 0.6 
~ i.v. 5 20 19.0 3.0 
~ l.p. 7 16 15.6 !.51 0.25-0.50 < 0.9 
~ l.V. 9 17 16.2 2.1! 
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Effect cif one serum injection 
It was investigated how long after skin grafting passive enhancement could 
still be obtained (table 14). Only one injection of antiserum was used. An 
injection on the second day after transplantation still resulted in optimal pro-
longation of graft survivaL After day 4 no enhancement occurred. Surprisingly, 
a slightly earlier rejection was noted when the serum was injected on the 7th 
day after transplantation. One injection of 0.2 ml anti-31 serum appeared to 
be less effective than injections every other day (table 15). Doses varying from 
Table 14. BH1·D: skin graft to B6AF1 recipients. Effect of one injection of anti-31 serum 
(0.20 ml) on different days after skin grafting. 
controls sex 
B0AF1 0 ~ 
B0AF1 3 
serum 
injection 
on day n 
45 
24 
x s.d. Pstudent Pwncoxon 
9 1.32 
11.6 1.21 
0 
~ 18 14.6 1.50 0 < 0.00001 0.0000000003 
I! 
I! 
3 
3 
3 
3* 
2 
4 
5 
6 
7 
10 14.8 
9 15.0 
10 12.8 
9 12.7 
7 14.7 
9 10.3 
* shorter survival time than controls B6AF 1 6 
2.04 0.00005 0.000002 
1.32 0.00001 0.0000008 
1.81 < 0.10-0.05 0.025 
2.96 0.50-0.20 0.176 
4.46 0.20--0.10 0.071 
1.41 0.05-0.02* 0.017* 
Table 15. Effect of different dosages of anti~31 serum on the enhancement of B10.D2 skin grafts in B6AF 1 
recipients 
serum injections 
1 X or 
sex multiple dosejinj. n M.S.T. x s.d. Pstudent Pwncoxon 
controls I! 45 9 9.4 1.32 
controls 3 24 II 11.6 1.21 
I! lx 0.20 ml 24 15 14.7 1.96 < 0.0005 < 0.0000000001 
I! multiple 0.20 ml 31 16 16.7 2.52 < 0.001-0.0005* < 0.014* 
same I! lx 0.05 ml 6 15 14.5 0.84 < 0.0005 < 0.00001 
serum I! lx 0.20 ml 5 15 15.2 2.59 0.30--0.60 •• < 0.6** 
same 3 lx 0.01 ml 5 14 14.0 1.0 0.0025-0.05 < 0.0004 
serum 3 IX 0.10 ml 4 14.5 13.5 3.32 0.40--0.80*** < 0.9*** 
3 lx 1.0 ml 5 14 14.2 1.79 0.40-0.80 *** < 0.8*** 
* compared to the group with one serum injection 
** compared to the group with an injection of 0.05 cc serum 
*** compared to the group with an injection of 0.01 cc serum 
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0.01 ml to 1.0 ml in males and 0.05 ml to 0.30 ml in females did not induce 
different degrees of enhancement. 
Apparently only a small dose is sufficient for the attainment of enhancement. 
In this experiment, the prolongation of graft survival by one injection seems 
more significant with the use of female recipients. However, the two sera were 
not part of the same batch. 
Specificity qf the anti-31 serum (table 16) 
The specificity was tested by transferring the serum to (129xA)F1 mice and 
Cs,BLf,o mice, which were subsequently grafted with a B10.Dz skin. The 
Cs,BL/w mice are coisogenic with the B,o.Dz mice and differ at the H2-allele, 
including 5 H2-specificities in addition to the 31-specificity. The histo-incom-
patibility in the combination B1o.D2 -> (129 xA)F, consists of the H2-3l-
specificity and non-H2-loci. In this last group no significant difference in 
survival time occurred between the control group and the recipient treated 
with serum. However, anti-31 serum induced a slight prolongation of graft 
survival time in the Cs,BL/w mice. Apparently the monospecific anti-31 serum 
can also exert a weak enhancing effect on the other 5 H2-specificities. 
Table 16. Specificity of anti-31 serum. B10.D2 skin grafts to Cu~BL/10 and (129 X A)F 1 mice. 
recipient anti-31 serum n M.S.T. x s.d. Pstudent Pwncoxon 
Cto1BL/1o 10 9.5 9.7 !.85 
Cr;7BL/10 + 9 12 ll.S 1.42 0.025 < 0.07 
(129 X A)F, 5 12 ll.8 !.92 
(l29xA)F, + 13 13 12.5 !.56 0.25-0.50 < 0.5 
Effect of anti-31 serum in immunized recipients 
The anti-31 serum was tested in recipients that were sensitized either by a 
previous skin graft or by an injection with donor-cells. A second skin graft was 
applied after the wound of the first graft healed, i.e. about 14 days after rejection. 
The rejection of a second skin graft could not be influenced by antiserum, 
when the first skin graft was rejected in a normal time. This is in accordance 
with the findings of other investigators. Enhancement of a second set response 
has up till now never been reported. 
In contrast a group of20 BsAF1 females, which were also treated with anti-31 
serum during the first skin graft procedure, rejected a second Bw.Dz skin graft 
at a later time. Thus enhancement of a second skin graft is possible, provided 
that the anti donor serum is injected· not only in the second but also the first 
skin grafting procedure (fig. 9). 
The anti-31 serum was also effective when given together with an otherwise 
60 
100 
80 no~rum 
20 
0 
2 
' 
6 
L__ 
' . 
' ! 
' ' ' . I ._ ___ 1 
' . 
' 
' 
' i 
L._. 
' jenh:lnced group ... anti-st'rum 
i__."! 
-----~ ! 
l ' -·-· 1+ant1-serum ! 
' ' 
' 1----·-----· 
I 
8 10 12 
" 
16 
days after transplantation 
without antiserum 
with anti-31 serum. 
with anti-31 serum. The recipients were also treated with anti-31 serum during 
the first skin graft procedure. 
n M.S.T. s.d. Pstudent Pwncoxon 
20 
11 
20 
7 
7 
9.5 
1.24 
0.93 
1.83 < 0.0005 
Fig. 9. Effect of anti-31 serum on the survival of second B10.D2 skin grafts. 
< 0.0001 
sensitizing i.v. injection of viable cells (fig. 10). One injection ofl8-30 X 106 viable 
B10.D2 lymphoid cells, given a few hours before skin grafting, resulted in a 
slightly accelerated rejection ofB10.D2 skin grafts. When however anti-31 serum 
was added to the cell suspension and subsequently injected every other day, 
prolongation occurred. One B10.D2 skin was even tolerated for more than 
150 days, after an i.v. injection of 42 X 106 viable B10.D2 spleen and lymphe 
node cells was given. With the two higher doses the prolongation of graft 
survival was more pronounced than with anti-31 serum alone. Apparently a 
mi.'Cture of donor antigens and anti-donor antibodies may also induce enhance-
ment and even at a much more significant level when the appropriate cell 
dosage is used. 
Effect qf irradiation in addition to serum treatment 
Antiserum injections used in combination with irradiation, caused a very long 
prolongation of graft survival time. B,AF 1 male mice were irradiated with 
400 R total body dose, 24 hours before skin grafting. Anti-31 serum was given 
every other day. The control group, which was only irradiated, did reject the 
B10.D2 skin grafts in 16 days M.S. T. The M.S. T. in the experimental group 
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was 39 days, while 4 skin grafts were tolerated for more than 70 days. Enhance-
ment did not manifest itself, when the irradiated B6AF1 mice were injected on 
the day of transplantation with 100 X 10• viable spleen and lymphe node cells, 
collected from those hyperimmunized B6AF1 mice, which were the source of 
the enhancing anti-31 serum (fig. II). 
Thus enhancement of skin grafts is much more pronounced when the treat-
ment with anti donor serum is combined with irradiation. 
Effect of multiple injections of hyperimmune anti-32 serum 
In addition to the H2-31-specificity, the 32-specificity of the H2-locus was 
also tested. For this purpose, B10.BR (32+) skin grafts were applied to B.AF, 
(32-) recipients. This again is a monspecific coisogenic combination, where 
the recipient only differs from the donor at the H2-32-specificity (table 6). The 
rejection reaction was much weaker in this combination than was the case 
with the H2-31 barrier (fig. 12). Again a difference existed between the im-
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mune response of males and females (p < 0.01). Multiple injections of0.2 ml 
hyperimmune anti-32 serum in B6AF1 mice, induced a significant prolon-
gation ofB10.BRskin graft survival. Enhancement of skin grafts then is feasible 
with anti- 31 and -32 serum in host-donor combinations differing for the H2-31-
and H2-32-specificity respectively. 
H2-31- and H2-32-specificity 
In this experiment anti-31 and anti-32 serum were tested in a hi-specific 
coisogenic co;_bination. (B10.D2XB1o·BR)F1 (31+, 32+) mice were the source 
of the donor skin for the B.AF1 (31-, 32-) recipients. In this combination, the 
recipients lack the 31 and 32 specificity of the H2-locus, which are present in 
the donor strain. The B.AF1-recipients were either treated with anti-31 serum, 
anti-32 serum or anti-31 an\1 anti-32 serum together (fig. 13). Surprisingly, 
significant extension of graft survival occurred with either the anti~31 or the 
anti~32 serum alone. The two sera, administered simultaneously, were not 
more effective than either of them alone. Thus no additive effect occurred of 
the two enhancing sera. 
100 
80 
20 
0 
-----
-----
........ 
i: 1: 
'--+--.~~;.:::.·.::-~;.;.-r······; 
1.---= 
' 
' 
' •·.::::.·4~ 
:L::.-~-
---1 
8 . 10 
controls 
anti-31 serum 
anti-32 serum 
anti-31+32 serum 
i controls 
L.---1 
I 
I 
I 
I 
12 
n 
8 
8 
8 
6 
16 
M.S.T. 
!! 
15.5 
15.5 
15 
""'-"""'"'-"'"'-"-'-''"'"--"'i 
' 
' ·······'·"".-,.-~--~ 
18 20 22 
' 
' 
' 
24 
days after transpla.!'tation 
s.d. Pstuctent Pwncoxon 
1.38 
4.07 0.01-0.002 0.0025 
3.58 0.01-0.002 0.0020 
4.32 0.20-0.10 0.08 
Fig. 13. B10 .D:::X B10BR skin grafts to B6AF1 Q. Effectofanti-31, anti-32 and anti-31+32serum. 
Antigenic Disparity: H2-31 +32 specificities. 
4. Discussion 
In the present experiments, in which mice coisogenic for the 31 and 32 alloan-
tigenic specificity of the H2-locus were used, enhancement of skin grafts was 
achieved by passive transfer of hyperimmune anti-donor serum. A prolonga-
tion in M.T.S. of B10.D2 skin grafts of 9 days occurred in the male B.AF 1 
recipients, which were injected with antiserum, directed against the H2-31 
specificity. The 31-specificity has all the characteristics of the strong H2-histo-
compatibility locus as far as the rejection of skin grafts is concerned. This is, 
however, only the case, when females are used. The female B6AF1 recipients 
rejected the B10.D2 donor skin graft earlier than the males. Females possess a 
stronger reacting immune system [165], but this has not been reported with 
skin grafts across the H2-barrier [16], except for thymectomised recipients 
[lOa]. In these experimental groups, where such a clear difference in immune 
reactivity exists between females and males, one would expect a much stronger 
enhancement in males, but this was not the case. 
The prolongation of skin graft survival by the action of anti-donor serum 
in such a simple coisogenic strain combination, provides an excellent model for 
the study of passive immunological enhancement. 
The 32-specificity of the D-end of the H2-locus appeared to be weaker in 
antigenic strength than the 31-specificity (K-end). The difference in immune 
response between male and female B6AF1 mice was in this case again apparent. 
Passive enhancement of B1o.Ba skin grafts by the transfer of monospecific 
anti-32 serum could be obtained in B,AF1 recipients. The anti-31 serum as well 
as the anti-32 serum induced enhancement of (B1a.D2 X B10Ba)F1 (31 +, 32+) 
skin grafts in B.AF 1 mice. 
Surprisingly no better enhancement was attained with the combined use 
of anti-31 and anti-32 serum. Thus, monospecific antisera could in this experi-
ment produce enhancement in a hi-specific coisogenic combination. This is in 
contradiction to the theory of Moller [189] that for a good immune in-
hibition, the enhancing antibodies should be directed against all the antigens of 
the donor. It might of course be possible that our antisera are not entirely mono-
specific but cross reacting with certain antigens. Our experiments prove that 
the anti-31 serum could even induce a slight prolongation of graft survival in 
a model, where the recipients did not only lack the H2-31-specificity, but also 
5 other H2-specificities. No effect was noted on the survival ofB10.D2 skin grafts 
in (129 XA)F1 mice, which lack the H2-31-specificity in addition to non-H2-
loci. 
Thus the monospecific anti 31-antibodies still have an enhancing effect in the 
presence of an incompatibility at SL'< H2-specificities, but none when also 
non-H2 loci are involved. It has always been a controversial point, whether 
such antibodies are effective at the whole cell surface, or at the individual 
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antigenic determinants [71, 116]. The present findings suggest that the anti-31 
antibodies can execute their enhancing effect because the six antigenic deter-
minants are close together on the cell surface or because they are similar in 
structure. A similar phenomenon might be the finding of Green bury and Moore 
[97] who reported the immunosuppressive effect of anti-Forsmann antibodies 
on the humoral response to the red cells in rabbits. To this phenomenon might 
also be related the naturally occurring protection against Rh immunization, 
afforded by A.B.O. incompatibility between mother and foetus. 
Little information is as yet available about the best time to administer the 
antiserum. Kaliss [137] was able to enhance tumor grafts up until ten days after 
the injection of the tumor cells. Dixon [71] reported the suppression of anti-
body synthesis in rabbits by anti Keyhole Limpet Hemocyanin (KLH) serum 
given 6-8 days after injection with KLH antigen. In our experiments one 
injection of anti-31 serum on the fourth day after transplantation could still 
provoke prolongation of skin graft survival time. On the fourth day after skin 
grafting the allo-antigen will already be recognized and antibody production is 
at this time usually at its peak. Yet on this day an antiserum injection is still 
effective. Thus the mechanism of enhancement is probably not purely afferent 
and the possibilities of a central or efferent inhibition of the rejection reaction 
arc still left. 
Different dosages are reported as the best way to induce passive enhancement. 
Either small [139, 190] or large [32, 206] doses were needed. Moller [190] 
even noted two different effects of anti-donor serum. With the same dosage of 
antiserum he obtained either enhancement or inhibition of tumor growth in 
mice, depending on the kind of tumor. In our experiments single injections of 
0.05 or 0.01 ml antiserum were only slightly less effective than an injection 
of 1.0 mL Hence even a small amount of antibody is sufficient to put the en-
hancing mechanism into action. 
In clinical transplantation several immunosuppressive reagents are used 
together to deal with the rejection reaction. It was therefore of interest to study 
the effect of our antiserum in combination with immunosuppressive treatment. 
Irradiation was used for immunosuppression, which appeared to work syn-
ergistically with the anti-31 serum. B10.D2 skin grafts enjoyed a very prolonged 
survival on irradiated B6AF 1 mice, which were treated with antiserum. Anti-
serum producing lymphoid cells were in this model not effective at all. By in-
hibiting the immune response in the early phase with irradiation, the anti-
serum apparently has a better opportunity to induce its enhancing effect. 
Irradiation might give the antibodies the chance to exert their enhancing 
effect before the lymphoid cells of the recipient are recovered and finally enter 
the skin graft. 
It has in general been impossible to induce enhancement in previously 
sensitized animals. Also in our studies a second skin graft could not be enhanced 
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by antiserum. However, when the recipients were previously treated with 
anti-31 serum during the first skin graft period, a second Bro.Dz skin graft 
enjoyed a prolonged survival. Apparently enhancing antibodies affect the 
immune mechanism in such a way, that enhancement may again occur with 
a second skin graft. This is very suggestive for an enhancing activity at the 
central level, for stimulation of the immune mechanism did already take 
place during the first skin graft period. The enhancing anti-31 antibodies 
could also counteract the effect of an otherwise sensitizing injection of viable 
B1o.Dz lymphoid cells and even cause a stronger enhancement than with serum 
alone. In one case the Bro.Dz graft was not rejected at all! 
Thus sensitization by lymphoid cells does not occur when the cells are mi.xed 
with the anti-31 serum. This strongly suggests that the cellular response is 
blocked at the peripheral level by the antiserum. The humoral response then 
might be left, which can sustain the formation of enhancing antibodies, whereas 
the originally injected antibodies are already destructed [81]. The effectiveness 
of antigen-antibody precipitates in preventing the immune reaction has also 
been described for other experimental models [9, 116, 270, 278, 279]. 
5. SUDlmary 
Passive enhancement of skin allografts was achieved in mice. Several findings 
in these experiments give information about the mechanism of enhancement. 
Firstly, enhancement could still be passively obtained up to 4 days after 
transplantation. This excludes the possibility of an afferent mechanism. 
Secondly, enhancement of a second skin graft appeared to be possible, provided 
that the recipients were also injected with antiserum during the first skin graft 
procedure. A central blockage of the immune response can be the only 
explanation for this finding. 
Furthermore the most significant enhancement was obtained by a combi-
nation of anti-31 serum with either irradiation or the administration of viable 
donor cells. Donor antigens as well as irradiation affect the immune response 
at the central level. Thus the present experiments manifest the possibility of 
enhancement of skin grafts and offer speculations about its mechanism. 
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CHAPTER VIA 
ENHANCEMENT AND ACCELERATED REJECTION 
OF MALE SKIN GRAFTS IN ISOGENIC POSTPARTUM 
FEMALE MICE, AS RELATED TO THE 
BREYERE AND BARRETT PHENOMENON 
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I. Introduction 
Breyere and Barrett described in 1960 [35] a decreased resistance of post-
partum females to tumor grafts of tbe male strain with which they had been 
bred. This effect increased with parity and also occurred with male skin grafts 
[36, 37, 38, 39, 40, 221, 300]. Some investigators related this phenomenon to 
a state of tolerance, induced by the continuous contact of the motber with the 
antigens of the conceptus [37, 38, 39, 40, 221]. An argument against this 
theory is the demonstration in multiparae of humoral [147, 148, 149, 118] and 
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cellular [259] immunity against the antigens of the male strain. This suggests 
that enhancement is the causative mechanism. 
The purpose of the present experiments was to test whether enhancement 
might indeed be the cause of the Breyere and Barrett phenomenon. 
Multiparous female mice were bred with males of the same strain. Thus the 
only antigenic difference was determined by the HY-locus. This locus was 
discovered by Eichwald and Silmser in 1955 [77]. The rejection by females of 
an isogenic male skin will occur in many inbred strains of mice. The HY-locus 
is strongly expressed in the Cs,BLjmice. Here the antigen determined by the 
HY-locus is as potent as the antigens of the other histocompatibility loci in the 
mouse, except for the H2-locus [25, 26, 159, 285]. It has always been assumed 
that this male antigen was determined by theY-chromosome [77, 25, 26, 219, 
241]. There is however also some evidence for an autosomal determination of 
the HY-locus [285, 80]. 
2. Material and methods 
Animals 
The following strains were used: Cs,BL/10, Cs,BL/s, B1o.Dzjnew, Blo-129 (21 M). 
The retired breeders were not older than 1 year. The number of their preg-
nancies was unknown. Virgins were only used when 8 weeks or older. The 
multiparae were divided into many different groups, according to the ship-
ments from Jackson Laboratory, Bar Harbor. The number of pregnancies of 
the individual animals has not been recorded. They were guaranteed to 
have had several litters before being shipped. 
Serum 
The mice were bled from the retro-orbital sinus of the eye. The blood was al-
lowed to clot at room temperature and kept overnight at +4 °C. The serum 
was pooled and stored at -20°C. The PVP-method of Stimpfling [268] was 
used to detect haemagglutinating antibodies and the test of Boyse, Old and 
Chouroulinkov [29] for cytotoxic antibodies. 
Skin grafts 
These were applied following the technique of Billingham and Medawar [24]. 
Parabiosis 
Parabiosis was performed by the technique of Sauerbruch and Heyde [237], 
joining the two animals' peritoneal cavities by suturing the peritoneum and 
by joining the muscles and skin from ear to tail. 5-0 catgut was used for the 
peritoneum and muscles and 4-0 silk for the skin. To avoid the post-operative 
complication of separation of the two animals, interrupted sutures were used 
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Fig. 14. A multiparous Cr.7BL/10 mouse in parabiosis with a Cr,7BL/10 virgin. 
for the skin and the scapulae were joined with a silk suture. Only the couples 
that remained in good condition were used in the experiments [fig. 14). Sur-
gical separation was a simple and fast procedure. The mice tolerated the separa-
tion with subsequent skin grafting without difficulty. 
3. Results 
Controls 
30 Cs,BL/ro male skin grafts displayed a rather short survival time on Cs,BL/1o 
females, with a Mean Survival Time (x) of 21.2 days, s.d. 9.58. As is shown in 
fig. 15, 30 female Cs,BLj, mice rejected an isogenic male skin graft later with 
a 5i of 26 days, s.d. 8.87 and a survival time ranging from 19-57 days. A large 
spread exists in the survival times of the individual grafts, as is to be expected 
in the presence of weak antigenic differences [123]. 
Experimental groups 
According to the literature, multiparous females will reject isogenic male skin 
grafts much later or not at all (fig. 16+17). This however was not always the 
case in our experimental 209 multiparous C57BL/ro and C5,BLj, females. 
Table 17 shows the results with the various multipara groups. 
Many isogenic male skin grafts did not enjoy an extended survival time, but 
instead were rejected in either a normal time or even in an accelerated way 
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Fig. 15. Isogenic male skin grafts to female C;;7BL/6 and C~>7BL/10 mice. 
Fig. 16. Cr;7BL/n male skin graft 60th day after transplantation to C 57BL/0 multipara. 
(table 17). The total number of 150 Cs,BLJ6 multiparae did not reject an iso-
genic male skin graft significantly later. A striking effect was noted with some 
experimental groups. These multipara groups (Ib and IIb) displayed an 
accelerated rejection (fig. 18). 
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Also B10.Dz retired breeders (fig. 19) rejected B1o.Dz male skin grafts earlier 
than B10.Dz virgins. No correlation was noted between the period of time that 
the skin grafts were applied after the arrival of the mice in the laboratory and 
the time of rejection. 
Table 17. Isogenic male skin grafts to female Cr;7BLfv. (I) and Cu7BLh0 (II) multiparae. 
Groups I and II were divided in sub-groups~ respectively la-k and IIa-e according 
to their time of arrival from Bar Harbor. 
C 117BL/6 male skin grafts to C;;7BL/0 multiparae 
group I n x (days) s.d. (days) Pstudent Pwncoxon 
controls: (virgins) 30 26.0 8.87 
multiparae 
IA I b 9 47.1 22.04 0.05--0.02 0.013 
I a 9 40.1 23.62 0.20~0.10 0.17 
Ik 5 35.0 0.00 < 0.001 0.005 
Ic 18 31.3 9.88 0.10~0.05 0.006 
If 10 30.5 5.23 0.10-0.05 0.004 
Ih 15 29.3 1!.23 0.50~0.20 0.45 
Ij 27 27.9 1!.34 0.50~0.20 0.39 
Ii 24 26.8 8.96 > 0.50 0.42 
IB* Id I! 19.6 5.07 0.01~0.002 0.01 
Ie 16 20 6.93 0.05--0.02 0.085 
Ig 6 23.5 6.47 0.50~0.20 0.80 
IA+B I a tjm k !50 29.0 12.89 0.20~0.10 0.16 
Cr;7BL/1n male skin grafts to Cr;7BL/10 multiparae 
group II n x (days) s.d. (days) ± Pstudent Pwncoxon 
controls: (virgins) 30 2!.2 9.58 
multiparae 
IIA II a 9 39.3 24.08 0.10~0.05 0.016 
IIb 8 23.0 5.61 > 0.50 0.20 
IIc 1 I 23.9 5.49 0.50-0.20 0.034 
II B* IId 15 16.7 3.06 0.05--0.02 0.30 
IIe 16 20.6 7.64 > 0.50 0.90 
IIA+B IIatfme 59 23.4 12.62 0.50~0.20 0.20 
* accelerated rejection 
Second set response 
The few multiparous C,,BL/, mice which accepted male skin grafts for a 
prolonged period were tested with a second skin graft. The first male skin 
grafts were excised when still 100% viable for more than 30 days after grafting. 
Fig. 20 shows that the second skin grafts also survived longer on these multi-
parae. A few multiparae received a third graft. In these animals the rejection 
occurred at a later time too. 
72 
100 
90 
80 
70 
60 
~ 
~ .. 
~50 
" ~ 
- 40 ~ 
"" oc 030 
z 
"' ~20 
10 
f- MULTIPARA 
:. ... 
·---··: ______________________ _ 
3 6 912151821242730333639424548515457606365697275 
DAYS 
n x 
controls (virgins) 30 26.0 
- - - - - multiparae 33 38.3 
Fig. 17. Isogenic male skin grafts to C 57BLJ c females. 
100 
90 
so 
70 
~ so 
~ 
> so oc 
" ~ 
MULTIPARA-
-
40 
~ 
"" oc 0 30 
z 
"' ~ 20 
;;' 
10 
s.d. 
8.87 
17.67 
Pwncoxon 
< 0.001 
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 DAYS 
n 
controls (virgins) 30 
- - - - -multiparae II 
26 
19.6 
Fig. 18. Isogenic male skin grafts to Ca7BL/(I females. 
s.d. 
8.87 
5.07 
Pwncoxon 
0.01-0.02 
73 
100 
90 
80 
70 
60 
50 
40 
~ , 30 
> 
"' :::> 
"' 
20 
... 
10 
·-. 
'--' 
VIRGINS-
MULTIPARAE-
·------------
' 
'-------------------------------------· 
2 6 10 14 18 22 26 30 34 38 42 46 50 54 58 62 
DAYS AFTER TRANSPLANTATION 
n ii Pstudent 
virgins 
- - - - - multiparae 
9 
25 
35 
20.1 
s.d. 
19.53 
14.07 0.10-0.05 
Fig. 19. Isogenic male skin graf's to B10.D~ virgins and multiparae. 
100 
90 
so 
70 
20 
' 
-- -------------·---·-----·---·-·-·-· 
: ! 
: ! 
-- -------------------------- -~--- ------· ------, 
; ' i__________ i-3rd GRAFT 
' 
2nd GRAFT-! 
I '--··------··--, i:t..!..-; 
! 
' !tt ' 
---------·-·----! 
' 
' 
Pwncoxon 
< 0.01 
10 jtt :·---·-·-·-----j 
16 18 20 22 24 26 28 30 32 34 36 38 
n ii 
controls (virgins) 30 26.0 
----- I 2nd skin graft 11 37.2 
----- II 3rd skin graft 4 33.5 
of group I 6 were killed with 100% viable skin grafts 
of group II 2 were killed with 100% viable skin grafts 
... 
40 42 44 46 48 50 52 54 56 58 
DAYS AFTER TRANSPLANTATION 
s.d. Pstudent Pwncoxon 
8.87 
10.27 < 0.01 0.002 
9.00 0.20 0.10 
66 70 
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Passive transfer 
Serum obtained from multiparous Cs,BL/6 mice, was injected in amounts of 
0.2 ml i.p. in isogenic virgins (fig. 21). One group received one injection. 
Another group received 14 injections, one every other day. The isogenic male 
skin grafts enjoyed an extended survival in both groups. Apparently one in-
jection of antiserum is in this experiment as effective as multiple injections. 
Serology 
The haemagglutinin and cytotoxin titers were tested in the pooled sera of 
several multipara groups. No haemagglutining or cytotoxic antibodies could 
be detected. 
Parabiosis 
Cs,BL/lo multiparae were joined in parabiosis with C57BL/10 virgins. After 
one month of parabiosis they were separated and on the same day grafted with 
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a Cs7BL/10 male skin. Only animals without post-operative complications were 
used in these experiments. 
C57BLj10 virgins, after parabiosis with multiparae, accepted male skin grafts 
for a much longer period than virgin controls, as is shown in fig. 22. A normal 
rejection of skin grafts from B10.129 (21 M) mice occurred in Cs,BL/1o virgins, 
which had been in parabiosis with isogenic multiparous females for four 
weeks (fig. 23). 
4. Discussion 
The purpose of these experiments was to distinguish between enhancement and 
tolerance in the phenomenon of Breyere and Barrett, i.e. the acceptance of male 
skin- and tumor-grafts by the multiparae with which they had been bred 
[35, 36]. 
Tolerance has predominantly been accepted as the mechanism of this phe-
nomenon, as no proof for enhancement existed. A naturally occurring coisogenic 
intrastrain combination, differing in the BY-locus served as a model for our 
experiments. This locus manifests itself as a rather strong locus in the Cs,BL 
mice. 
Cs,BL female multiparae, mated within the strain, in some instances tolerated 
the isogenic male skin grafts for a longer time than nulliparae, as was expected 
from the experience of Breyere and Barrett. 
In contrast, however, some groups displayed an accelerated rejection of the 
male skin grafts, which suggests that they were sensitized in the course of their 
pregnancies. Thus a variety of rejection patterns was exhibited by the various 
multipara groups as they were purchased from Bar Harbor, which manifested 
itself in both increased and decreased male skin graft survivals. It might be-
possible that the contact with foetal antigens either induces a sensitization or 
an impaired immunological response. Enhancement then seems the most 
likely explanation for the Breyere and Barrett phenomenon, because in con-
trast to tolerance, both immunity and enhancement depend on the presence 
of the immune response and not on its absence. 
The results with the passive transfer of serum from multiparae furnish additional 
proof for enhancement. This test, which is crucial for enhancement, was con-
trived by injections of serum from multiparae into isogenic virgins and by 
parabiosis of a multipara and a nullipara. In both cases a prolongation of male 
skin graft survival occurred. By parabiosis, however, a much longer prolonga-
tion was obtained, probably because of the more continuous and complete 
exchange of serum between the partners. In such an isogenic combination a 
common blood circulation is established within a few days after parabiosis is 
performed [171]. Transfer of cellular immunity is then also possible and one 
might expect a second set response in the virgins. Instead, a reduction in 
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immunological responsiveness occurred in the virgins after parabiosis with 
multiparae. Apparently, the enhancing antibodies, are able to inhibit the 
existing cellular immunity. The immunological specificity of this effect was 
proven by the normal rejection of B,o.129 (21 M) skin grafts by C57BLJ10 
nulliparae, which had been in parabiosis with multiparae. In this combination 
an incompatibility exists at the weak H4-locus, which was used to reveal any 
non specific effect which might be more obvious in respect of a weak histo-
compatibility antigen. 
The observation in our experiments of both prolonged survival and accelerated 
rejection suggests that virtually every multipara is sensitized by foetal antigens. 
Indeed haemagglutinins and leukagglutinins against H2-antigens of the male 
partner have been also demonstrated in the serum of postpartum female mice 
[!47, 148, !49, 118]. In addition to humoral immunity, cellular immunity also 
seems to exist in the postpartum female. This has been reported by Soren [259]. 
He demonstrated that lymphoid cells of multiparae evoke an intensified graft 
versus host reaction in their newborn offspring. 
The expected second set response to a male skin graft in the multiparae might 
be inhibited by enhancing antibodies. Enhancement then appears to be re-
sponsible for prolongation of graft survival and for the normal rejection times 
in the bulk of the multipara groups. Indeed second and third male skin grafts 
were also accepted for a longer time, when grafted on to selected multi parae 
which already displayed enhancement. 
Thus every pregnancy induces a sensitization towards the foetal antigens, 
which in most cases is masked by the occurrence of enhancing antibodies. In 
such a way the foetus itself can also be protected from immunological rejection 
by cells. The foetus indeed seems a naturally occurring exception to the rule 
that grafts exchanged between non-identical individuals will be rejected. 
Several theories have been proposed to explain this phenomenon [6, 69, 125]. 
Enhancement however might be the cause for the take of a foetus. 
5. Summary 
The acceptance of male skin grafts by the post partum femals with which they 
had been bred (Breyere and Barrett phenomenon) is mediated by enhancing 
antibodies as shown by passive transfer of antibodies, respectively by parabiosis 
and passive immunization. 
Sensitization of multiparous females towards male antigens appears to 
occur, that probably in most cases results in the occurrence of enhancing 
antibodies. 
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CHAPTER VI B 
FURTHER INVESTIGATION INTO THE MECHANISM 
OF ENHANCEMENT IN THE 
BREYERE AND BARRETT PHENOMENON 
I. Introduction 
There are two important alternatives to explain the mechanism of immunolog-
ical enhancement. One centres about some sort of specific inactivation of the 
immune response in the lymphoid centres themselves, while the other depends 
upon a peripheral masking of the antigenic specificities of the transplant itself 
by bound antibody molecules. These two modes of action need not, of course, 
be mutually exclusive. 
The following experiments were designed to reveal information about these 
two alternatives. The experimental model, described in the previous experi-
ment, was used for the study of the mechanism. Enhanced skin grafts 
were transferred to normal recipients, isogenic to the mice, that carried the 
graft before (fig. 24). 
virgin multipara 
Fig. 24. Transfer of enhanced male skin from multiparous mouse to virgin. 
2. Material and methods 
Normal adult C"BL/6, Cs,BL/10 and Cs,BL/10-LP mice were used throughout. In 
the Cs,BL/strains the HY-locus exerts an obvious effect in that male to female 
grafts are predictably destroyed. Multiparous Cs,BL/6 females were healthy 
retired breeders acquired from the Jackson Memorial Laboratory in Bar 
Harbor, Maine. 
3. Results 
Cs,BL/6 male skin grafts were rejected with a MST of 26 ± 8.87 days (stan-
dard deviation of the mean) by adult virgin females, whereas their survival on 
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multiparous female recipients was extended to a MST of 35.9 ± 15.63 days. 
A graft was considered to be clearly enhanced if it was still 100 per cent viable 
at more than 10 days beyond the MST of the control group, since more than 
90 per cent of control recipients had rejected their grafts by this time. 
Secondary transfer of enhanced male skin grafts to adult females did not 
result in survival beyond that expected for normal male skin grafts. Indeed these 
grafts were rejected more rapidly than normal skin, as the MST of 15 second-
arily transferred Cs,BLf• male skin grafts was 17.6 ± 7.64 days rather than 
the 26,0 ± 8.87 days MST expected of normal skin (fig. 25). That the trauma 
of secondary transfer was not, in itself, an independent cause of this more rapid 
rejection was assured by the fact that enhanced male skin grafts survived in-
definitely when placed upon isogeneic males. 
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The peculiar behavior of enhanced grafts on secondary transfer to normal 
recipients was emphasized by an experiment in which two skin grafts were 
simultaneously grafted from male Cs,BL/10 donors to multiparous Cs,BL/10 
recipients. When both were shown to be enjoying enhanced survival, one graft 
from each recipient was transferred secondarily to an isogenic female. In all 
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instances the secondarily transferred graft was rejected significantly in advance 
of its partner which remained on the multiparous recipient (see fig. 26). 
Using Cs,BL/s mice in 17 instances male skin grafts were applied to normal 
females simultaneously with previously enhanced male skin grafts. In this 
experiment the previously enhanced grafts were rejected with an MST of 
18.6 ± 7.30 days whilst the grafts from normal donors were rejected with an 
MST of 21.3 ± 9.44 days (see fig. 27). Both skin grafts were thus rejected at 
about the same time, a time significantly earlier than expected for normal skin. 
This again is an argument against a traumatic cause of the earlier rejection, 
for in that case one would not expect a more rapid rejection of normal grafts. 
In an effort to shed some further light on this apparently non-specific effect, 
enhanced male Cs,BL/w skin grafts were transferred instead to C57BL/loLP 
male recipients. In this situation the recipient is presented not with the male-
specific histocompatibility antigen(s) against which the enhancing antibody 
was directed but with the specificity determined by the H3-locus. Such grafts 
between normal individuals are rejected with an MST of 24 ± 4.9 days. 
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C5,BL/6 male grafts, which have undergone enhancement on Cs,BL/6 females 
were, however, rejected much earlier by Bw.LP male recipients with an MST 
of 14.3 ± 2.69 days (see fig. 28). 
4. Discussion 
These observations do not seem to support the concept that immunological 
enhancement is a consequence of a peripheral effect, such as might occur if 
the histocompatibility antigens of the donor celles were masked by specific 
antibody. On the other hand, they suggest that enhanced skin grafts are 
peculiarly vulnerable to rejection when they are placed in an appropriate 
environment. 
Indeed such enhanced skin grafts appear to have tbe capacity of provoking 
a heightened response on the part of normal individuals after secondary 
transfer. A potentiating effect between serum antibody and sensitized cells has 
previously been reported by others [14, 15] and such an effect may be opera-
tive with regard to the enhanced graft secondarily transferred to a normal reci-
pient. A contribution toward this effect could also come from recipient leuko-
cytes already mobilized into the base of the graft which are then carried with 
it onto the second host. Such sensitized "passenger" cells might contribute to 
the more rapid generation of a specific response in secondary recipients which 
would then cause an accelerated rejection of both the previously enhanced 
grafts and simultaneously placed normal grafts. 
5. Sununary 
Enhanced male skin grafts appear to be particularly vulnerable to rejection 
after transfer to an isogenic nulliparous female. Thus enhancing antibodies 
do not seem to exert any protective effect on the graft itself. 
The accelerated rejection of the enhanced grafts was even experienced to 
a lesser degree by simultaneously placed normal isogenic male skin grafts. The 
possible mechanism of this phenomenon is discussed. 
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CHAPTER "VII 
PASSIVE ENHANCEMENT OF SKIN HETEROGRAFTS 
IN RATS 
mouse 
1. Introduction 
Heterografts and heterologous serum were explicitly excluded in the definition 
of enhancement, given by Snell [257]. Acceptance of heterologous grafts has 
been shown before with the use of ALS. Heterologous tumor grafts were also 
tolerated after pretreatment with lyophilized tissue early after birth [215]. 
However, the authors did not differentiate between tolerance and enhance-
ment. Broder e.a. [ 41] reported the engendered growth of a mouse tumor in 
guinea pigs by incubation with Fab-fragments of isologous anti-tumor serum. 
In the experiments described in this chapter an attempt was made to obtain 
enhancement of heterologous skin grafts. The results suggest that the extended 
survival of mouse skin grafts, observed in rats treated with antiserum, has 
been caused by immunological enhancement [130a]. 
2. Material and methods 
Adult rats of the local inbred R strain and the inbred Wistar Wag/Ry strain 
weighing respectively 250-300 gm and 150-200 gm served as recipients for 
skin heterografts. Donors were Cs,BLj, mice and guinea pigs. The experi-
mental groups were injected intraperitoneally with 0.3-0.5 ml rabbit anti-
mouse serum (R.A.M.S.), starting the day before transplantation. The serum-
injections were continued for the first two days and subsequently every other 
day until day 17. 
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This antidonorserum (A.D.S.) was raised in rabbits by weekly injections 
in the footpads of 50-100 X 10' viable spleen- and lymphe node-cells from 
C57BL}s mice with complete Freund's adjuvant. The rabbits were bled by 
cardiac puncture at different times after various immunizations. The skin 
grafts were transplanted following the technique of Billingham and Medawar 
[24]. Rejection was determined by macroscopical examination of the grafts. 
A chronic rejection pattern occurred in the rats, which were treated with 
antiserum. The reaction was characterized by progressive oedema and scab-
formation. Serum and red cells were obtained by cardiac or retro-orbital sinus 
puncture from rats and mice respectively. For absorption studies I ml of the 
A.D.S. was incubated for 1 hour at 37 'C with 7 X JOS viable rat spleen cells. 
Horse anti-mouse and anti-rat lymphocyte sera (H.A.M.L.S. and 
H.A.R.L.S. respectively) were kindly provided by the Radiobiological Insti-
tute, T.N.O. Rijswijk. 
Cytotoxicity was determined by the micro titer method of Kissmeyer Nielsen 
as modified by van Rood [224]. Haemagglutinins were demonstrated by 
Stimpfling's method [268]. Both the Student Welch test and Wilcoxon test 
were applicated for evaluation of statistical significance. 
3. Results 
Cs,BL/• skin grafts were rejected by R- and Wistar-rats in 6-8 days (M.S.T. 
7 days, s.d. 0.61). Although the cytotoxic ef!ect of normal rabbit serum on rat 
cells has been reported [66], no effect of normal rabbit serum was noted on the 
survival of mouse skin grafts iri. rats. Treatment of the recipients with A.D.S. 
(anti-donor serum), raised in rabbits, resulted in a striking prolongation of 
Cs,BL/• skin graft survival up to 38 days (M.S.T. 19 days, Pstudent < 0.0001, 
Pwncoxon < 0.001, see fig. 29+30). 
A rather chronic rejection occurred in the experimental animals treated 
with A.D.S., in contrast to the rapid rejection of skin grafts by untreated con-
trols. Another difference was the greater spread in survival times of the Cs,BL 
skin grafts in the treated rats. This type of rejection is characteristic for a weak 
histo-incompatibility. 
It appeared that the A.D.S. should be prepared according to strict rules. 
Firstly, a long interval between collection and last injection of a hyper-
immunization schedule is prerequisite for an effective serum. Significant pro-
longation of skin graft survival only occurred with those sera which were 
collected on the 15th day and later after the last immunization (see fig. 31). 
The effect of the A.D.S. seems to decrease, when obtained more than 49 days 
after the last immunization. Apparently, the formation of effective antibodies 
continues for a long time. 
A relation seems also to exist between the number of immunizations and the 
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Fig. 29. Mouse skin graft on 32nd day after transplantation to rat. 
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effectiveness of the sera (fig. 32). The most significant prolongation of graft 
survival was obtained with those sera that were collected after 14 weeks of 
immunization. These conditions also apply for sera to be used for the attain-
ment of passive enhancement and antibody mediated humoral unresponsiveness 
and not for A.L.S. Various authors noted that enhancing sera could be best 
obtained long after the last injection of a hyperimmunization scheme, sug-
gesting a change in antibodies after a certain time. 
Secondly the addition of Freund's adjuvant to the cell suspension was found 
to be essential. In order to obtain a maximal extension of graft survival, the 
recipient should receive a sufficient number of serum injections. One injection 
on the day of transplantation or three injections on day minus one, zero and 
the day after transplantation did not influence the graft survival as significantly 
as did injections every other day after transplantation (fig. 33). Cytotoxic 
and haemagglutinating antibodies were present in very low titers in the rats 
tolerating the mouse skin grafts for a prolonged period. This might be an 
indication that central or afferent blockage of the immune response is the 
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Fig. 34. Microscopy of mouse skin graft 28 days after transplantation to rats. 
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cause of this phenomenon rather than efferent blockage. The abscence of 
signs of lymphocyte infiltrations and other immune reactivity in the surviving 
grafts, also seems to argue against efferent blockage (fig. 34). 
Many sera with high haemagglutinating and cytotoxic titers procured 
heterograft acceptance, whereas sera with titers lower than 256 were not 
effective (see fig. 35). For unknown reasons, some rabbits never produced en-
hancing sera, in spite of high titers. The question arises what mechanism 
might be responsible for the immunological unresponsiveness towards hetero-
grafts. Although the immunization schedules used seem to differ from those 
usually employed for the preparation of A.L.S., an A.L.S. effect should be 
more convincingly excluded. Indeed cross reaction of the R.A.M.S. with rat 
antigens existed. Antibodies against rat lymphoid and red blood cells were 
present, although to a lesser degree than the anti-mouse antibodies. To 
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eliminate the anti-rat antibodies of the R.A.M.S., the serum was absorbed 
with 7 X lOB rat spleen and lymphe node cells per ml and subsequently injected 
into rats (see fig. 36). After absorption anti-rat titers reached much lower levels 
up to 1 : 16. Although the capacity of these sera to prolong skin graft survival 
was diminished, a significant effect on the heterografts remained. 
The following experiment also seemed to exclude a simple A.L.S.-effect. In 
addition to a mouse skin graft, a guinea pig skin graft was applied to rats, 
which were treated with A.D.S. Assuming the existence of a recipient-specific 
A.L.S.-effect [13] one might expect an extended survival of both grafts. 
Immunological enhancement however is donor-specific and would only lead 
to acceptance of the mouse skin grafts. Indeed the guinea pig skin grafts were 
rejected in a normal period in contrast to the prolonged survival of the mouse 
skin grafts (see fig. 37). Yet a greater incompatibility probably exists between 
guinea pigs and rats. In that case the difference in graft survival of guinea pig 
and mouse skins could be partially explained by this discrepancy in histo-
incompatibility. 
One more argument against antiwlymphocyte antibodies being the active 
principle in A.D.S. was obtained by comparing a strong H.A.R.L.S. with our 
A.D.S. in the mouse skin to rat system. A.D.S. was much more effective than 
H.A.R.L.S. in prolonging heterograft survival, while the effect of H.A.R.L.S. 
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on allografts was among the best ever observed with A.L.S. preparations 
(fig. 38). Moreover, when H.A.R.L.S. was given in doses similar to those ofthe 
A.D.S., little effect on the heterografts was observed (fig. 39). Finally, an effec-
tive H.A.M.L.S., when employed as A.D.S., was not able to procure significant 
prolongation of heterograft survival. 
4. Discussion 
The results of these preliminary experiments indicate that at least in the mouse 
to rat combination, enhancement of heterografts is feasible. Enhancement of 
heterologous skin grafts has so far not been reported. A preferable method for 
the demonstration of enhancement is its passive transfer by serum. 
In this experimental model A.D .S. produced a striking prolongation of mouse 
skin graft survival up to 38 days. Realizing the possibility of cross reactivity 
with rat cells, much effort was directed towards the exclusion of an A.L.S. 
effect of the A.D.S. Several findings were in contradiction with an A.L.S. 
activity. For the attainment of an effective A.D.S., a stringent immunization 
schedule must be followed, dissimilar to the A.L.S. immunization schedules 
usually employed. The necessity of collecting the serum late after hyperimmuni-
zation and of avoiding intravenous immunization and the indispensability of 
Freund's adjuvant are not typical requirements for the preparation of A.L.S. 
[70, 162, 247]. On the other hand, immunological enhancement has also mostly 
been induced with late hyperimmune sera. For humoral unresponsiveness too, 
the sera were collected at a time that antibodies occurred with a high affinity 
for antigenic determinants. Furthermore the activity of A.D.S. seems to be 
dependent upon high cytotoxic and/or haemagglutinating titers in contrast to 
A.L.S .. Sera with low titers were not effective. 
The activity of A.D.S. could not be completely removed by absorption with 
rat cells. The latter finding indicates a specificity of the sera for donor antigens. 
Such a specificity for the antigens of the donor is characteristic for enhance-
ment4 
The difference between an A.L.S. and A.D.S. also became apparent in a 
different effect on heterograft survival. A much more pronounced accepq.nce 
ofheterografts occurred with the use of A.D.S., whereas the H.A.R.L.S. (A.L.S.) 
produced very extended survivals of rat allografts. If A.D.S. acts as an A.L.S., 
it would be an unbelievably potent one. Moreover, no effect was obtained with 
H.A.R.L.S., when this A.L.S. was administered in the same doses as A.D.S. 
Neither did H.A.M.L.S. produce extended survivals. 
All these results can be taken as evidence for enhancement as the cause of the 
prolonged survival of these heterografts. The absence of antibodies in the serum 
of rats displaying enhancement and the absence of histological reactions in 
the accepted grafts, suggest a central or afferent inhibition of the Immune 
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response, because in those cases a cellular and humoral response are not elicited. 
In conclusion enhancement may occur in a heterologous host-donor com-
bination. 
5. Sununary 
Prolongation of mouse skin grafts on rats by an anti-donorserum (A.D.S.) is 
demonstrated. Several findings suggest that enhancement causes this effect. 
The methods for the preparation of the A.D.S. differ considerably from the 
immunization schemes of A.L.S. 
The effectiveness of an A.D.S. absorbed with rat cells and the normal rejec-
tion of a simultaneously placed guinea pig skin graft, were also not in favor of an 
A.L.S. effect. Furthermore, a much better prolongation of heterograft survivals 
was obtained with A.D.S. than with A.L.S. When administered in the same 
dosage as A.D.S., A.L.S. was not effective. The absence of antibodies and of a 
histological reaction in the accepted grafts, suggests a central or afferent 
inhibition. 
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CHAPTER VIII 
GENERAL DISCUSSION AND CONCLUSIONS 
The results obtained from the present experiments shed some light on the 
multiple problems of enhancement. Since Casey reported in 1932 the ,xyz"-
effect or the enhanced tumor growth rate by "enhancing material" many in-
vestigations about this subject have followed, which were summarized in 
several reviews [33, 127, 139, 146, 150, 232, 257]. Immunological enhance-
ment has been readily demonstrated with tumor allografts, whereas normal 
tissues were rather resistant to passive or active enhancement. Since the develop-
ment of the technique of grafting vascularized organs in rodents, enhance-
ment has been reported with vascular allografts [87, 98, 101, 167, 211, 212, 
269,270]. 
Yet, attempts to produce enhancement of skin allografts were relatively un-
successful [22, 34, 60, 99, 119]. Either higher antigenicity of the epithelial 
tissue and a different vascular composition than tumor tissue and vascular 
organs, or a completely different type of rejection of skin grafts, as compared 
to vascularized grafts, might be responsible. In this respect the use of organ-
specific antibodies might be important for the attainment of enhancement. The 
enhancing sera for tumors were usually prepared by injection of tumor tissue 
whereas the sera employed for the enhancement of skin graft were raised by 
lymphoid cell injections. The finding that rat skin tissue and bone marrow 
may share antigenic determinants that are not present on isologous lymphe 
node cells [242] could partly explain those results [30]. Obviously, it is of great 
importance to obtain enhancement of normal grafts. Eventual clinical appli-
cation can only be based upon extensive experimental experience with en-
hancement of normal instead of tumor grafts. The outcome of the enhance-
ment of skin grafts might be a useful indicator for the effectiveness of enhance-
ment in the clinical situation. 
1. Enhancement of allografts (chapters IV, V, VI A, VI B) 
One of the most interesting aspects of our studies was that enhancement of skin 
grafts has consistently been obtained. Active as well as passive enhancement of 
skin grafts could be induced reproducibly in coisogenic strains of mice, i.e. 
strains that are genetically identical, except for a single specificity at the major 
histocompatibility locus. One might argue that such a small genetic disparity, 
as in this case, at the 31 specificitity of the H2-locus would facilitate any 
attempt to affect the rejection reaction. However, B,o.Dz (31 +) skin grafts 
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were rejected by BsAF 1 (31-) controls in as short a time, as occurs across the 
strong H2-locus. Furthermore, the study of such weak transplantation antigens 
is of great value for clinical transplantation, because the improvements in 
tissue typing enable transplantation between matched individuals. At the 
present time the difference in histocompatibility antigens between donor and 
recipient can be carefully measured. For example, many well-matched donor-
recipient combinations have been used in Eurotransplant [225]. Thus weak 
histo-incompatibilities frequently occur in clinical transplantation not only in 
related, but even in unrelated donor-recipient combinations. 
The principal reason that coisogenic combinations were tested, was that at-
tempts to produce enhancement across the strong H2-locus had so far been un-
successfuL It was also assumed that effective specific antisera could more 
readily be produced in combinations with a monospecific disparity. This was 
indeed the case, for active as well as passive enhancement have consistently 
been produced in this modeL 
Pretreatment of the B6AF1 recipients with either B10.D2 lymphoid cells 
(active enhancement) or BsAF1 anti-B10.D2 serum (passive enhancement), led to a 
significant prolongation of Bro.D2 graft survivals. Passive enhancement was also 
demonstrated across the 32-specificity of the H2-locus as well as across the 31-
and 32-specificity together, which involved the enhancement of respectively 
B10.BR and (B10.D2 X B1o-BR)F 1 skin grafts in pretreated BsAF 1 recipients. Inter-
estingly, a synergistic effect was noted between irradiation of the recipient and 
treatment with anti-31 serum. 
Furthermore, enhancing antibodies also seem to circulate in multiparous 
mice, for it was demonstrated that the Breyere and Barrett phenomenon is based 
upon immunological enhancement. Enhancement of skin grafts occurred in 
multiparous females, using the male Y antigen as antigenic difference. In other 
words, the Breyere and Barrett phenomenon or the prolonged acceptance by 
postpartum females of tumor and skin grafts of the male strain with which they 
had been mated, is mediated by enhancing antibodies. 
Thus, these experiments demonstrate that both active and passive enhance-
ment of skin grafts can be consistently obtained in certain mouse models. The 
importance of this finding is, that in such simple models, the mechanism of 
enhancement and the structure of the enhancing antibodies can be studied. 
2. Enhancement of heterografts (chapter VII) 
Realising that the possibility to prolong graft survival is inversely related to the 
strength of the histo-incompatibility [121, 176, 177], a much stronger anti-
genic barrier was also tested. To this end, heterografts were studied instead of 
allografts. Between two species a stronger rejection reaction will be provoked 
than between members of the same species, for the magnitude of antigenic 
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difference is determined by the genetic disparity. Rats were chosen as reci-
pients of mouse skin grafts, because of the evidence in the initial studies of 
Stuart for enhancement of vascularized grafts in this species. Chapter VII 
reveals that enhancement can be passively induced in a hetero-specific com-
bination. Mouse skin grafts enjoyed a prolonged survival of up to 38 days in 
rats by the administration of late hyperimmune rabbit anti mouse serum. 
3. Interpretation of the experimental data 
Previously, heterografts had never been used in enhancement studies. There-
fore, the concept of enhancement, which was restricted to the prolongation of 
allograft survival by allo-antiserum [25 7, 256], can now be extended to 
heterografts and heterologous serum. The effectiveness of enhancing sera in 
passive enhancement does not only seem to depend upon the genetic disparity, 
but also upon a specific production method of the sera. 
Characteristic for an enhancing antiserum is the specificity towards donor 
antigens. It is an anti-donor serum and hence in these experiments denoted 
as A.D.S. It might even be important to use tissue-specific antigens for the 
preparation of A.D.S. intended for enhancement of a particular organ. Males 
have usually been employed preferentially for the induction of enhancement, 
because of their weaker immune response compared to females. In chapters 
IV and V, the difference in immune response even became apparent in a faster 
rejection by female mice of skin allografts incompatible at the 31- and 32-
specificity of the H2-locus. Yet in these experiments no significant difference 
was noted in the degree of enhancement in females and males. 
The physiological role of immunological enhancement is currently a matter 
of speculation. A regulatory function of antibodies by means of a feedback 
mechanism became apparent in the experiments with antibody mediated 
humoral unresponsiveness. This homeostatic mechanism may prevent excess 
antibody formation. Many different immunological homeostatic mechanisms 
probably exist in animals and man. The control mechanisms that govern the 
rate of cell division, or the occurrence of tumor cells, may be either humoral 
- by antibodies directed against new antigens on those cells - or intercellular 
by contact inhibition of cell proliferation [ 48]. Disturbance of one or more of 
these control mechanisms may give rise to the growth of tumors. Tumors, 
possessing specific antigens, might be protected from being rejected by en-
hancing antibodies. This mechanism has indeed been demonstrated by Hell-
strom e.a. [112, 115] for instance in patients with either melanoma, colon-
carcinoma or neuroblastoma. They developed an in vitro assay of lymphocyte-
target cell interaction. Serum of tumor bearing patients contained factors that 
blocked the inhibiting effect of the lymphocytes of the patient on tumor colony 
forming. These blocking factors disappeared during regression of the tumor. 
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Homeostasis might also be interrupted by immunosuppression and it has been 
reported that a higher incidence of tumors occurs in patients undergoing 
immunosuppressive treatment. 
Another activity of enhancement might take place in the remedy of bac-
terial diseases by preventing the occurrence of antigenic competition. Anti-
genic competition comprises the suppression of the immune response against 
a certain antigen by the simultaneous elicitation of a response to a second an-
tigen [78]. Such an immune suppression could promote the multiplication of 
bacterial cells and in this way sustain infectious diseases. Enhancing anti-
bodies might eliminate antigenic competition by blocking one of the antigens 
and thus enable a normal immune response to occur against the other antigen 
[217]. 
From the results, described in chapter VI, it appears that immunological 
enhancement is involved in the protection of the foetus. The foetal antigens 
are different from those of the mother and thus are an exception to the rule 
that grafts containing transplantation antigens will be rejected when placed 
in a genetically different surrounding. The various explanations for this phe~ 
nomenon [6, 69, 125] have subsequently been contradicted. Pregnant females 
do seem immunologically competent. Controversy also exists about the 
anatomical barrier that prevents either a sensitization or rejection. There are 
supporters of an intrinsic antigenic deficiency of the trophoblast or its coating 
by an inert substance like mucoprotein. In contradiction to such a barrier is the 
evidence for feto-maternal transfer of lymphocytes and materno-fetal transfer 
ofigG [288]. 
Chapter VI reveals the existence of sensitization of multiparous females to-
wards the male antigens and the occurrence of enhancement, proven by 
passive transfer of antibodies, by means of parabiosis and passive immunization 
respectively. Hellstrom [114] described an in vitro protective effect of a serum 
factor present in pregnant mice on foetal cells in the presence of isologous 
immune lymphe node cells. Thus immunological enhancement seems to occur 
in pregnant and multiparous mice. Enhancing antibodies may in some way 
protect the foetal graft and abortus may result from the abscence of those anti-
bodies. It might be interesting to investigate why the enhancing antibodies are 
so readily formed in this graft-host relation and whether the sera of human 
multiparae also harbour enhancing antibodies. 
4. Mechanism of enhancement 
The mode of action of enhancing antibodies is still not understood. The 
occurrence of enhancement or rejection might depend upon the balance be-
tween enhancing antibodies and those antibodies which cause rejection in 
cooperation with the cellular reaction. In our experimental models passive 
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enhancement was used in preference, since the induction of enhancement by 
active immunization can be easily confused with the induction of tolerance. 
These experimental models enabled us to investigate the basic problems of 
enhancement. 
Male skin grafts, that exhibited enhancement on multiparous mice, were 
transferred to isogenic normal females. The accelerated rejection of such grafts 
seems to argue against the concept of an efferent mechanism of enhancement. 
However, it does not completely exclude such a mechanism, because it re-
mains possible that sensitized leucocytes and/or antibodies present in those 
transferred grafts, are no longer inhibited by the circulating enhancing anti-
bodies. Although it is still generally accepted that antibodies alone do not 
play an important role in skin graft rejection, some investigators reported a 
destructive effect of antibodies on skin grafts [15, 61, 63, 64, 106, 107, 204, 
262]. A dual effect of the same antiserum has also been reported [43]. Such an 
effect probably also plays a role in another experiment described in this thesis. 
Hyperimmune A.D.S., which induced immunological enhancement of skin 
allografts in mice, induced a slightly accelerated rejection of the skin allografts 
when injected once on the 7th day after transplantation. 
Enhancing sera might thus be able to support and accelerate an already 
active rejection reaction. Whether "enhancing" antibodies support or inhibit 
immune reactions may well depend on the state of the host and the quality and 
distribution of various antibodies in the serum. 
Two findings excluded an afferent blockage. The effectiveness of one in-
jection of A.D.S. on the 4th day after transplantation in mice can not easily be 
explained by an afferent effect. This leaves us with two other explanations for 
the mechanism of enhancement, namely central and efferent inhibition of the 
immune response. The synergism of A.D.S. with simultaneously injected donor 
cells suggests that the immune apparatus is not affected centrally during en-
hancement. 
In the case of an efferent blockage one would expect the immune reaction 
to occur in the presence of a live graft. Yet, in the rats with enhanced mouse 
skin grafts, antibody titers could not be demonstrated, although simple 
methods were used. A cellular infiltration was not present in the enhanced 
grafts. Furthermore, enhancement of a second skin allograft could be achieved 
in mice, provided that hyperimmune A.D.S. was injected during the first skin 
graft procedure. At the time that the second skin is grafted, passively trans-
ferred antibodies will not be left in the recipient in view of the short half-life 
time of mouse antibodies. Hence in this case the immune mechanism and 
memory probably have not been affected at the efferent level. 
Investigations of antibody mediated humoral unresponsiveness, a phenom-
enon that might be closely related to enhancement, indicate the importance of 
antigen-antibody interaction. For the occurrence of this phenomenon, all an-
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tigens have to be covered by antibodies. Likewise, following the theory of 
Moller, antibodies should be directed against all the antigenic determinants 
for the attainment of enhancement. Two observations were in contradiction 
with this theory. Firstly the occurrence of enhancement of mouse skin allo-
grafts by an A.D.S., which was only directed against one of the two existing 
antigenic determinants. Enhancement of (B10.D2 X B10.BR) (31 +, 32+) skin 
grafts occurred in BsAFr (31-, 32-) mice by the administration of anti-B10.D2 
serum. Secondly, an enhancing effect of anti-31 serum was even noted, when 5 
other H2-specificities were present in the donor. The effectivity of a mono-
specific enhancing serum in a model where more specificities are involved, 
indicates that either not all the antigens of the graft have to be covered by 
enhancing antibodies or that cross reactivity exists. This finding is at variance 
with a peripheral blockage of enhancing antibodies. 
In conclusion, these various experiments could not provide evidence for 
the existence of one single mechanism of immunological enhancement \table 
18). Although the findings were mostly in favour of a central or afferent 
blockage, an efferent effect could not be excluded, especially in view of the 
impressive evidence for such a mechanism in the literature [99, 196]. It might 
be possible, that a combination of factors is operative in immunological en-
hancement. A protection of the graft at the efferent level may very well coincide 
with a central inhibition of the immune response. 
Table 18. Summary of those experiments in this thesis that give information about the 
mechanism of immunological enhancement. 
experimental model 
transfer of enhanced skin grafts (chapter VII B) 
effectiveness of one injection on the 4th day after 
transplantation (chapter V) 
synergism of A.D.S. and donor cells (chapter IV) 
synergism of A.D.S. and irradiation (chapter V) 
enhancement of second skin grafts (chapter V) 
no antibody titer in enhanced rats 
no cellular infiltration in enhanced grafts (chapter (VII) 
* + : probably the acting mechanism 
probably not the acting mechanism 
±: can not be excluded as the acting mechanism 
5. Conclusion 
mechanism of enhancement* 
afferent central 
± + 
+ 
+ 
+ ± 
± + 
+ + 
efferent 
± 
+ 
+ 
+ 
The feasibility of the enhancement of skin allo-and heterografts as shown in the 
described experiments, opens the possibility for speculation about clinical 
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application. If these results can be repeated in other species and with vascul-
arized organs, then immunological enhancement might provide a solution for 
some of the clinical transplantation problems. Enhancement could then also 
be applied to heterologous organ transplantation, which might be the future 
of clinical transplantation [222] because of the problems around allo-trans-
plantation [261, 262]. The shortage of suitable organs imposes a restriction to 
allo-organ transplantation. Immunological enhancement could also be applied 
to human allografts, either by specific heterologous A.D.S., or homologous 
A.D.S. from multiparae. A.D.S. treatment could be combined with low doses 
of A.L.S. or other immunosuppressiva, for in the experimental model, de-
scribed in chapter V (fig. 11), a synergistic effect of A.D.S. with irradiation and 
later with A.L.S. was noted [174]. 
Due to the present immunosuppressive treatment, many of the trans-
planted patients die of infection and some may develop tumors. Enhancement 
would probably avoid these complications. Although it is tempting to test en-
hancement in clinical transplantation, this should not be undertaken until 
enhancement is reproducibly attained in other species like dogs or monkeys 
and until more information is available about the mechanism and the exact 
structure of the antibodies, that are causing enhancement. 
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SUMMARY 
The experiments described in this thesis concern the enhancement of skin allo-
grafts and heterografts in mice and rats respectively. Immunological enhance-
ment of skin grafts could reproducibly be obtained in these experimental 
models. Before, enhancement had only been described for tumors and recently 
for vascularised grafts. The results of our experiments are described in the 
following chapters. All the data were statistically evaluated. 
Chapter IV dealt with the effect of active immunization of the recipient with 
frozen-thawed or viable donor tissue. This resulted either in sensitization or 
active enhancement, depending on the route of administration, the number of 
injections and the time interval between the last injection and skin grafting. 
Even a second set response could be abolished in this experimental model. 
In chapter V passive immunization of mice was studied. Antisera could be 
raised that, after passive transfer, consistently produced passive enhancement of 
mouse allografts. This model enabled further studies about the mechanism of 
enhancement. One of the findings was that passive enhancement of skin allo-
grafts could be obtained up to 4 days after transplantation. This excludes the 
possibility of an afferent mechanism. 
The occurrence of active as well as passive enhancement appeared to depend 
upon a special hyperimmunization scheme. The same immunization method 
was successfully used for the attainment of good rabbit anti-mouse serum in 
the experiments concerning the enhancement of skin heterografts in rats. Be-
sides such an artificial form of enhancement, induced by passive or active 
immunization, a naturally occurring form of enhancement appeared to exist in 
multiparous mice. Male skin grafts are known to be accepted for a longer 
period by isogenic multiparous females ( Breyere and Barrett phenomenon). In 
chapter VI A it is demonstrated that this phenomenon is caused by an enhancing 
factor in the serum of multiparous mice, as proven by parabiosis of multiparous 
and nulliparous females and by passive transfer of this effect to nulliparous 
females. It is concluded that any pregnancy leads to a sensitization towards 
the foetal antigens. The effect of the sensitization is probably in most cases 
abolished by enhancing antibodies. 
In chapter VI B the mechanism of enhancement in multiparous mice was 
studied by transferring enhanced skin grafts from multiparous mice to nulli-
parous mice. It appeared that the enhanced grafts were particularly vulner-
able to rejection after the transfer. This makes a protective effect of the en-
hancing antibodies on the graft itself unlikely. 
A synergistic effect was observed between passive enhancement and either 
irradiation of the recipient or treatment with donor cells. Although this 
finding suggests a peripheral mechanism of enhancement, other experimental 
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results denoted an inhibition of the immune response at the central or afferent 
level. For example, immune inhibition at the central level probably played a 
role in two experiments. One showed passive enhancement of a second mouse 
skin graft under appropriate conditions, the other an accelerated rejection of 
an enhanced skin graft after transfer from a multiparous to a nulliparous 
mouse. One single mechanism in the phenomenon of enhancement could not 
be demonstrated in spite of these and other data. 
In chapter VII skin heterografts were tested in rats after the successful attempts 
to produce enhancement of skin allografts. Rats were chosen as recipients of 
the heterografts, because of the evidence for enhancement of vascular allografts 
in this species in the initial studies of Stuart [269]. It could be demonstrated 
that passive enhancement of mouse skin heterografts may be obtained in rats, 
although a strong histo-incompatibility exists in this combination. 
One of the findings that may bring us closer to the study of enhancement in 
man is the effectiveness of a heterologous rabbit anti-mouse serum in rats as de-
scribed in the last experiment [130]. Yet, because of the various still unknown 
factors, clinical application of enhancement should not yet be attempted. 
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SAMENVATTING 
De experimenten, die in dit proefschrift beschreven zijn betreffen de enhance-
ment van huid allografts en heterografts in respectievelijk muizen en ratten. 
Immunologische enhancement van huidtransplantaten kon in deze experi~ 
mentele modellen bij herhaling verkregen worden. Voorheen was enhancement 
alleen aangetoond met tumoren en onlangs ook met gevasculariseerde trans-
plantaten. De resultaten van de hier vermelde experimenten zijn in de 
volgende hoofdstukken beschreven. Alle gegevens werden statistisch geeva-
lueerd. 
Hoofdstuk IV behandelt het effect van actieve immunisatie van de ontvanger 
met donorweefsel. Dit resulteerde hetzij in sensitisatie of actieve enhancement, af-
hankelijk van de wijze van toediening, het aantal injecties en het tijdsinterval 
tussen de laatste injectie en huidtransplantatie. Zelfs een second set response 
kon worden te niet gedaan in dit experimentele model. 
In hoofdstuk V werd passieve immunisatie van muizen bestudeerd. Antisera 
konden vervaardigd worden, welke bij herhaling passieve enhancement van 
muizen allografts veroorzaakten. Dit experimentele model maakte verdere 
onderzoekingen van het mechanisme van enhancement mogelijk. Een van de 
bevindingen was dat passieve enhancement van huid allografts nog tot 4 dagen 
na de transplantatie verkregen kon worden. Dit sluit de mogelijkheid van een 
afferent mechanisme uit. 
Ret voorkomen van actieve zowel als passieve enhancement bleek af-
hankelijk te zijn van een speciaal hyperimmunisatie schema. Dezelfde immuni-
satiemethode werd met succes toegepast bij het verkrijgen van een effectief 
konijnen anti-muizen serum in de experimenten betreffende enhancement van 
huid heterografts in ratten. N aast een dergelijke artificiele vorm van enhance-
ment, veroorzaakt door passieve of actieve immunisatie, bleek er ook een na-
tuurlijke vorm van enhancement te bestaan bij muizen. Het was reeds bekend 
dat mannelijke muizenhuid transplantaten voor langere tijd worden ge-
accepteerd door isogene multiparae dan door nulliparae (Brryere en Barrett-
fenomeen). In hoofdstuk VI A wordt duidelijk gemaakt dat dit fenomeen wordt 
veroorzaakt door een bepaalde factor in het serum van de multiparae. Dit 
werd bewezen met parabiosis van een multipara en een nullipara en met pas-
sieve ,transfer" van dit effect naar nulliparae. Uit de experimenten kwam naar 
voren dat elke zwangerschap tot sensitisatie voor foetale antigenen leidt. Ret 
effect van de sensitisatie wordt waarschijnlijk in de meeste gevallen teniet ge-
daan door enhancing antistoffen. 
In hoofdstuk VI B werd het mechanisme van enhancement bestudeerd in 
multiparae door ,enhanced" muizenhuidtransplantaten over te plaatsen van 
multiparae naar nulliparae. De ,enhanced" transplantaten bleken na het 
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overplaatsen versneld afgestoten te worden. Dit sluit een beschermend effect 
van de enhancing antistoffen op de transplantaten zelf uit. 
Een synergistisch effect werd waargenomen tussen passieve enhance:n~nt en 
zowel bestraling van de ontvanger, als behandeling van de ontvanger met 
donorcellen. Hoewel deze bevinding een perifeer mechanisme van enhancement 
aangeeft, duidden andere resultaten meer op een centrale of a:fferente inhibitie 
van de immuunreactie. Een verhindering van de immuunreactie op centraal 
niveau speelde waarschijnlijk een rol in twee experimenten. Een toonde aan 
dat passieve enhancement van een tweede muizenhuid onder bepaalde con~ 
dities mogelijk bleek, het andere beschreef de versnelde afstoting van een 
,enhanced" huidtransplantaat na overplaatsing van een multipara naar een 
nullipara. Ondanks deze en andere bevindingen kon een enkel mechanisme 
van immunologisch enhancement niet aangetoond worden. 
In hoofdstuk VII werden huid heterograjts getest in ratten na het succes met de 
enhancement van huid allografts. Ratten werden gekozen als ontvangers van 
de heterografts, omdat Stuart onlangs in deze diersoort de enhancement van 
gevasculariseerde allografts had aangetoond. Hoewel een sterke histo~incom­
patibiliteit bestaat in de muis-rat combinatie kon passieve enhancement van de 
muizenhuid heterografts verkregen worden. Een van de bevindingen, die ons 
dichter bij de bestudering van enhancement bij de mens brengt, is het goede 
effect van een lzeteroloog konijn anti-muizenserum in ratten, zoals beschreven in 
het laatste experiment [!30]. Echter, gezien de nog vele onbegrepen factoren 
lijkt klinische toepassing van enhancement nog niet gerechtvaardigd. 
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